,coef,coef_graph,coef_combined,coef_combined_zscore,coef_combined2
5-Phosphoribose 1-diphosphate biosynthesis,2.788144e-06,2.0,2.788144e-06,-0.095396265,0.33525938
A tetrasaccharide linker sequence is required for GAG synthesis,9.2006585e-06,8.0,9.2006585e-06,-0.0906014,0.06656699
ABC transporters in lipid homeostasis,1.9688076e-05,9.0,1.9688076e-05,-0.08275959,0.027100677
ADP signalling through P2Y purinoceptor 1,6.644037e-05,14.0,6.644037e-05,-0.04780124,-0.17343928
ADP signalling through P2Y purinoceptor 12,0.0007351802,13.0,0.0007351802,0.45223925,0.24937207
AKT phosphorylates targets in the cytosol,8.40614e-07,13.0,8.40614e-07,-0.096852496,-0.16507751
AKT phosphorylates targets in the nucleus,1.9402176e-05,8.0,1.9402176e-05,-0.08297336,0.07232457
AKT-mediated inactivation of FOXO1A,2.865302e-09,4.0,2.865302e-09,-0.09747892,0.24291688
ALKBH2 mediated reversal of alkylation damage,9.899004e-13,2.0,9.899004e-13,-0.09748106,0.3336858
ALKBH3 mediated reversal of alkylation damage,2.4448037e-09,3.0,2.4448037e-09,-0.09747923,0.28830191
AMPK inhibits chREBP transcriptional activation activity,2.596382e-06,6.0,2.596382e-06,-0.09553965,0.15361014
APC truncation mutants are not K63 polyubiquitinated,0.0,1.0,0.0,-0.09748106,0.37907103
APC truncation mutants have impaired AXIN binding,2.611348e-06,10.0,2.611348e-06,-0.09552847,-0.027922401
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,2.678236e-05,42.0,2.678236e-05,-0.07745494,-1.4666085
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,5.864677e-07,6.0,5.864677e-07,-0.09704253,0.15247577
APOBEC3G mediated resistance to HIV-1 infection,5.5301236e-08,4.0,5.5301236e-08,-0.097439714,0.24294646
ARL13B-mediated ciliary trafficking of INPP5E,3.1825977e-07,3.0,3.1825977e-07,-0.09724308,0.28848013
ATF4 activates genes,9.189058e-06,2.0,9.189058e-06,-0.09061008,0.33887193
ATF6 (ATF6-alpha) activates chaperone genes,8.976405e-08,6.0,8.976405e-08,-0.097413935,0.15219544
ATP sensitive Potassium channels,3.1061467e-09,2.0,3.1061467e-09,-0.09747874,0.3336875
AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0003318869,32.0,0.0003318869,0.15068254,-0.8405599
AURKA Activation by TPX2,4.967375e-06,48.0,4.967375e-06,-0.09376678,-1.751232
AXIN missense mutants destabilize the destruction complex,6.9480365e-08,10.0,6.9480365e-08,-0.097429104,-0.029356986
Abacavir metabolism,1.5396719e-10,3.0,1.5396719e-10,-0.09748094,0.2883006
Abacavir transmembrane transport,0.0,1.0,0.0,-0.09748106,0.37907103
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway,4.022806e-07,2.0,4.022806e-07,-0.097180255,0.33391282
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,1.1094698e-06,2.0,1.1094698e-06,-0.09665147,0.33431196
Acetylation,0.0,1.0,0.0,-0.09748106,0.37907103
Acetylcholine Neurotransmitter Release Cycle,2.9317778e-07,6.0,2.9317778e-07,-0.09726184,0.15231025
Acetylcholine regulates insulin secretion,9.2633235e-07,6.0,9.2633235e-07,-0.09678841,0.15266758
Acrosome Reaction,0.0,1.0,0.0,-0.09748106,0.37907103
Activated NOTCH1 Transmits Signal to the Nucleus,1.132836e-05,20.0,1.132836e-05,-0.08901044,-0.4768551
Activated NTRK2 signals through CDK5,7.242886e-08,5.0,7.242886e-08,-0.097426906,0.1975709
Activated NTRK2 signals through FRS2 and FRS3,1.1033391e-07,7.0,1.1033391e-07,-0.09739856,0.10682181
Activated NTRK2 signals through FYN,9.757725e-07,5.0,9.757725e-07,-0.09675144,0.19808075
Activated NTRK2 signals through PI3K,9.4367994e-07,4.0,9.4367994e-07,-0.096775435,0.24344787
Activated NTRK2 signals through PLCG1,2.0844163e-10,2.0,2.0844163e-10,-0.09748091,0.33368587
Activated NTRK2 signals through RAS,2.5034825e-07,5.0,2.5034825e-07,-0.09729386,0.19767134
Activated NTRK3 signals through PI3K,5.498688e-07,5.0,5.498688e-07,-0.0970699,0.19784038
Activated NTRK3 signals through PLCG1,1.3579603e-07,2.0,1.3579603e-07,-0.09737952,0.33376244
Activated NTRK3 signals through RAS,4.8801803e-06,5.0,4.8801803e-06,-0.09383198,0.20028432
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,0.00097191904,11.0,0.00097191904,0.62925726,0.47375417
Activation and oligomerization of BAK protein,2.0781629e-07,3.0,2.0781629e-07,-0.09732567,0.28841782
Activation of AMPA receptors,0.0,1.0,0.0,-0.09748106,0.37907103
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,3.822325e-06,43.0,3.822325e-06,-0.09462297,-1.5249519
Activation of ATR in response to replication stress,1.0635555e-09,22.0,1.0635555e-09,-0.09748027,-0.57401854
Activation of BAD and translocation to mitochondria ,1.3174417e-07,10.0,1.3174417e-07,-0.09738255,-0.02932185
Activation of BIM and translocation to mitochondria ,7.649839e-06,3.0,7.649839e-06,-0.091761,0.29261798
Activation of BMF and translocation to mitochondria,1.4039858e-07,4.0,1.4039858e-07,-0.09737608,0.2429945
Activation of C3 and C5,0.0,1.0,0.0,-0.09748106,0.37907103
Activation of DNA fragmentation factor,2.9844833e-07,8.0,2.9844833e-07,-0.0972579,0.061542727
Activation of G protein gated Potassium channels,1.0007667e-09,10.0,1.0007667e-09,-0.097480305,-0.029395632
Activation of Matrix Metalloproteinases,1.3070295e-10,6.0,1.3070295e-10,-0.09748096,0.15214485
Activation of NF-kappaB in B cells,0.00019224595,46.0,0.00019224595,0.04626805,-1.5547645
Activation of NOXA and translocation to mitochondria,1.0232053e-05,4.0,1.0232053e-05,-0.08983019,0.24869007
Activation of Nicotinic Acetylcholine Receptors,7.611935e-07,4.0,7.611935e-07,-0.096911885,0.24334487
Activation of PPARGC1A (PGC-1alpha) by phosphorylation,5.1466394e-08,6.0,5.1466394e-08,-0.097442575,0.15217383
Activation of PUMA and translocation to mitochondria,2.1787685e-06,6.0,2.1787685e-06,-0.09585191,0.15337443
Activation of RAC1,3.5631473e-08,5.0,3.5631473e-08,-0.097454414,0.19755015
Activation of RAS in B cells,4.760433e-06,5.0,4.760433e-06,-0.09392152,0.20021673
Activation of SMO,3.2307566e-05,4.0,3.2307566e-05,-0.07332355,0.26114914
Activation of TRKA receptors,9.574669e-07,2.0,9.574669e-07,-0.09676512,0.33422616
Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.00012906594,44.0,0.00012906594,-0.0009738806,-1.4996518
Activation of gene expression by SREBF (SREBP),1.6166034e-05,17.0,1.6166034e-05,-0.08539314,-0.33796906
Activation of the TFAP2 (AP-2) family of transcription factors,4.878902e-06,4.0,4.878902e-06,-0.093832925,0.24566883
"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",3.3896642e-05,31.0,3.3896642e-05,-0.07213534,-0.96335566
Activation of the pre-replicative complex,4.065604e-07,22.0,4.065604e-07,-0.09717706,-0.57378966
"Activation, myristolyation of BID and translocation to mitochondria",1.517338e-06,4.0,1.517338e-06,-0.09634649,0.24377163
"Activation, translocation and oligomerization of BAX",8.22104e-08,3.0,8.22104e-08,-0.09741959,0.28834692
Acyl chain remodeling of CL,2.9993105e-06,6.0,2.9993105e-06,-0.095238365,0.15383753
Acyl chain remodeling of DAG and TAG,2.1909225e-06,4.0,2.1909225e-06,-0.09584283,0.24415179
Acyl chain remodelling of PC,6.332716e-06,9.0,6.332716e-06,-0.09274586,0.019563124
Acyl chain remodelling of PE,3.94419e-06,8.0,3.94419e-06,-0.09453184,0.06360033
Acyl chain remodelling of PG,2.0208123e-05,4.0,2.0208123e-05,-0.08237073,0.2543204
Acyl chain remodelling of PI,0.00015633421,4.0,0.00015633421,0.019415569,0.3311478
Acyl chain remodelling of PS,2.0041302e-06,4.0,2.0041302e-06,-0.0959825,0.24404638
Adrenaline signalling through Alpha-2 adrenergic receptor,5.262642e-09,2.0,5.262642e-09,-0.09747712,0.33368877
"Adrenaline,noradrenaline inhibits insulin secretion",1.16851936e-07,14.0,1.16851936e-07,-0.097393684,-0.21087122
Advanced glycosylation endproduct receptor signaling,9.991236e-07,10.0,9.991236e-07,-0.09673398,-0.028832315
Aflatoxin activation and detoxification,1.7321945e-06,6.0,1.7321945e-06,-0.09618584,0.1531224
Agmatine biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Alpha-defensins,2.122497e-05,2.0,2.122497e-05,-0.0816104,0.34566483
Alpha-oxidation of phytanate,2.4157966e-06,6.0,2.4157966e-06,-0.095674686,0.1535082
Alternative complement activation,5.4730084e-08,2.0,5.4730084e-08,-0.09744014,0.33371666
Amine ligand-binding receptors,7.766167e-07,5.0,7.766167e-07,-0.09690035,0.19796835
Amino acid transport across the plasma membrane,3.1744847e-05,11.0,3.1744847e-05,-0.07374431,-0.056865167
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,1.7896763e-08,52.0,1.7896763e-08,-0.097467676,-1.9355662
Amyloid fiber formation,2.7054595e-05,28.0,2.7054595e-05,-0.07725138,-0.83106136
Anchoring fibril formation,0.0,1.0,0.0,-0.09748106,0.37907103
Anchoring of the basal body to the plasma membrane,7.6931127e-07,63.0,7.6931127e-07,-0.09690581,-2.4343798
Androgen biosynthesis,1.7779134e-07,2.0,1.7779134e-07,-0.09734812,0.33378613
Antagonism of Activin by Follistatin,1.0673344e-09,3.0,1.0673344e-09,-0.09748027,0.2883011
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",2.9243441e-08,18.0,2.9243441e-08,-0.09745919,-0.39246166
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00014464767,21.0,0.00014464767,0.010677127,-0.44699705
Antigen processing: Ubiquitination & Proteasome degradation,1.6485338e-06,179.0,9.209686e-09,-0.09747417,-7.698572
Apoptotic cleavage of cell adhesion  proteins,1.1386009e-06,4.0,1.1386009e-06,-0.09662969,0.24355789
Arachidonate production from DAG,3.069719e-08,4.0,3.069719e-08,-0.09745811,0.24293259
Aryl hydrocarbon receptor signalling,1.3698968e-08,6.0,1.3698968e-08,-0.09747082,0.15215251
Assembly of active LPL and LIPC lipase complexes,6.35603e-07,8.0,6.35603e-07,-0.0970058,0.061733015
Assembly of the ORC complex at the origin of replication,0.0001819103,6.0,0.0001819103,0.038539723,0.25481206
Association of TriC/CCT with target proteins during biosynthesis,0.0044602756,28.0,0.0044602756,3.2376251,1.6709778
Astrocytic Glutamate-Glutamine Uptake And Metabolism,1.5655378e-06,4.0,1.5655378e-06,-0.09631045,0.24379882
Asymmetric localization of PCP proteins,8.307213e-06,39.0,8.307213e-06,-0.09126946,-1.3408799
Attachment of GPI anchor to uPAR,2.0335428e-06,5.0,2.0335428e-06,-0.095960505,0.19867775
Attenuation phase,0.0062025324,12.0,0.0062025324,4.5403724,3.380444
Autodegradation of Cdh1 by Cdh1:APC/C,2.8080021e-05,41.0,2.8080021e-05,-0.07648463,-1.4204909
Axonal growth inhibition (RHOA activation),2.9842198e-07,5.0,2.9842198e-07,-0.09725792,0.19769844
Axonal growth stimulation,3.8396106e-06,4.0,3.8396106e-06,-0.09461004,0.24508227
B-WICH complex positively regulates rRNA expression,0.0011489107,25.0,0.0011489107,0.7616002,-0.06174801
BBSome-mediated cargo-targeting to cilium,2.1993113e-05,8.0,2.1993113e-05,-0.08103603,0.07378685
BDNF activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.09748106,0.37907103
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,8.170381e-06,5.0,8.170381e-06,-0.09137178,0.20214126
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",6.13845e-06,5.0,6.13845e-06,-0.09289113,0.20099446
Basigin interactions,2.1645653e-06,9.0,2.1645653e-06,-0.09586254,0.01721069
Beta defensins,5.9520306e-05,5.0,5.9520306e-05,-0.05297562,0.23112234
Beta-catenin phosphorylation cascade,1.8977924e-05,11.0,1.8977924e-05,-0.08329059,-0.06407061
Beta-oxidation of pristanoyl-CoA,1.3766754e-06,5.0,1.3766754e-06,-0.09645168,0.19830701
Beta-oxidation of very long chain fatty acids,3.5539756e-08,8.0,3.5539756e-08,-0.09745449,0.06139435
Bicarbonate transporters,4.661295e-08,3.0,4.661295e-08,-0.09744621,0.28832683
Binding of TCF/LEF:CTNNB1 to target gene promoters,2.1430576e-06,7.0,2.1430576e-06,-0.095878616,0.10796906
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB,0.0,1.0,0.0,-0.09748106,0.37907103
"Biosynthesis of A2E, implicated in retinal degradation",9.363382e-07,2.0,9.363382e-07,-0.09678092,0.33421424
Biosynthesis of D-series resolvins,8.0400454e-08,4.0,8.0400454e-08,-0.09742094,0.24296065
Biosynthesis of DHA-derived sulfido conjugates,0.0,1.0,0.0,-0.09748106,0.37907103
Biosynthesis of DPAn-3 SPMs,3.9419194e-07,3.0,3.9419194e-07,-0.097186305,0.28852302
Biosynthesis of DPAn-6 SPMs,2.1198928e-06,2.0,2.1198928e-06,-0.09589594,0.33488223
Biosynthesis of E-series 18(R)-resolvins,1.6726639e-05,4.0,1.6726639e-05,-0.08497395,0.25235552
Biosynthesis of E-series 18(S)-resolvins,8.589146e-07,4.0,8.589146e-07,-0.09683882,0.24340001
Biosynthesis of aspirin-triggered D-series resolvins,3.1579617e-07,4.0,3.1579617e-07,-0.09724493,0.24309349
Biosynthesis of electrophilic Ï‰-3 PUFA oxo-derivatives,3.3489584e-07,2.0,3.3489584e-07,-0.09723064,0.3338748
Biosynthesis of maresins,2.10495e-08,2.0,2.10495e-08,-0.097465314,0.33369768
Biosynthesis of protectins,1.320519e-07,2.0,1.320519e-07,-0.097382315,0.33376032
Biotin transport and metabolism,0.00021364035,11.0,0.00021364035,0.0622654,0.04579376
Breakdown of the nuclear lamina,5.4891682e-08,3.0,5.4891682e-08,-0.09744002,0.2883315
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,1.973792e-06,13.0,1.973792e-06,-0.09600519,-0.16443796
Butyrophilin (BTN) family interactions,4.268319e-06,7.0,4.268319e-06,-0.09428948,0.10916852
C6 deamination of adenosine,9.04652e-12,2.0,9.04652e-12,-0.09748105,0.3336858
CASP8 activity is inhibited,6.5208184e-08,9.0,6.5208184e-08,-0.0974323,0.016025845
CD209 (DC-SIGN) signaling,5.2493822e-05,15.0,5.2493822e-05,-0.05822957,-0.22669573
CD22 mediated BCR regulation,2.5411742e-05,5.0,2.5411742e-05,-0.0784798,0.211872
CD28 dependent PI3K/Akt signaling,4.2515558e-06,13.0,4.2515558e-06,-0.09430201,-0.16315243
CD28 dependent Vav1 pathway,4.066746e-05,9.0,4.066746e-05,-0.067072555,0.038941108
CDC6 association with the ORC:origin complex,5.6683337e-05,7.0,5.6683337e-05,-0.05509692,0.13875072
CDK-mediated phosphorylation and removal of Cdc6,0.0007124434,44.0,0.0007124434,0.4352381,-1.1704028
CDO in myogenesis,5.637908e-05,18.0,5.637908e-05,-0.05532442,-0.3606587
CDT1 association with the CDC6:ORC:origin complex,0.00055385206,36.0,0.00055385206,0.31665376,-0.8968273
CHL1 interactions,2.7741885e-07,4.0,2.7741885e-07,-0.097273625,0.24307182
CLEC7A (Dectin-1) induces NFAT activation,3.4160888e-07,7.0,3.4160888e-07,-0.09722563,0.10695234
CLEC7A/inflammasome pathway,2.496821e-08,3.0,2.496821e-08,-0.097462386,0.2883146
COPI-dependent Golgi-to-ER retrograde traffic,5.7898567e-05,41.0,5.7898567e-05,-0.05418825,-1.4036617
COPI-independent Golgi-to-ER retrograde traffic,1.3282e-05,25.0,1.3282e-05,-0.087549634,-0.7026787
COPI-mediated anterograde transport,0.003320858,59.0,0.003320858,2.3856423,-0.37903386
COPII-mediated vesicle transport,0.00043871562,51.0,0.00043871562,0.23056215,-1.6425872
COX reactions,1.2136926e-08,2.0,1.2136926e-08,-0.09747198,0.33369264
CREB3 factors activate genes,0.00012484111,5.0,0.00012484111,-0.0041329344,0.26798835
CRMPs in Sema3A signaling,1.0409621e-07,7.0,1.0409621e-07,-0.09740323,0.10681828
CS/DS degradation,2.5713987e-05,7.0,2.5713987e-05,-0.0782538,0.12127211
CTLA4 inhibitory signaling,4.907847e-06,15.0,4.907847e-06,-0.09381128,-0.2535525
Ca2+ activated K+ channels,1.7783934e-08,3.0,1.7783934e-08,-0.097467765,0.28831056
Ca2+ pathway,0.0002142039,35.0,0.0002142039,0.062686786,-1.043134
Calcineurin activates NFAT,0.00011570768,7.0,0.00011570768,-0.010962329,0.17206311
Calcitonin-like ligand receptors,0.0,1.0,0.0,-0.09748106,0.37907103
Calmodulin induced events,2.5038742e-05,9.0,2.5038742e-05,-0.07875871,0.030120507
Calnexin/calreticulin cycle,4.5279943e-08,19.0,4.5279943e-08,-0.097447194,-0.43783784
Carboxyterminal post-translational modifications of tubulin,8.27909e-05,13.0,8.27909e-05,-0.035575368,-0.11882607
Cargo concentration in the ER,7.203038e-05,19.0,7.203038e-05,-0.04362139,-0.3972106
Cargo recognition for clathrin-mediated endocytosis,2.7674216e-06,60.0,2.7674216e-06,-0.095411755,-2.2970965
Carnitine synthesis,9.768742e-10,4.0,9.768742e-10,-0.09748033,0.24291582
Caspase-mediated cleavage of cytoskeletal proteins,2.5250104e-06,11.0,2.5250104e-06,-0.09559302,-0.073356375
Catecholamine biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Cation-coupled Chloride cotransporters,4.9244145e-06,3.0,4.9244145e-06,-0.0937989,0.2910798
Cell redox homeostasis,0.0,1.0,0.0,-0.09748106,0.37907103
Cellular hexose transport,4.774024e-07,8.0,4.774024e-07,-0.097124085,0.061643727
Centrosome maturation,7.9991205e-06,54.0,7.9991205e-06,-0.091499835,-2.0218325
Ceramide signalling,7.7163325e-09,2.0,7.7163325e-09,-0.09747529,0.33369014
ChREBP activates metabolic gene expression,1.2804692e-07,5.0,1.2804692e-07,-0.09738532,0.19760229
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,1.9977857e-09,6.0,1.9977857e-09,-0.09747957,0.15214589
Cholesterol biosynthesis via desmosterol,1.9398043e-05,2.0,1.9398043e-05,-0.08297645,0.3446337
Cholesterol biosynthesis via lathosterol,5.6851495e-05,2.0,5.6851495e-05,-0.05497118,0.36577186
Choline catabolism,7.120123e-06,2.0,7.120123e-06,-0.092157096,0.33770427
Chondroitin sulfate biosynthesis,1.0402192e-05,11.0,1.0402192e-05,-0.08970297,-0.06891061
Chylomicron assembly,6.081434e-10,2.0,6.081434e-10,-0.0974806,0.3336861
Chylomicron clearance,2.8915647e-05,2.0,2.8915647e-05,-0.07585981,0.3500053
Chylomicron remodeling,5.272859e-07,3.0,5.272859e-07,-0.09708679,0.28859812
Citric acid cycle (TCA cycle),2.7212049e-05,19.0,2.7212049e-05,-0.07713364,-0.42250532
Class C/3 (Metabotropic glutamate/pheromone receptors),4.0580206e-09,4.0,4.0580206e-09,-0.097478025,0.24291755
Classical Kir channels,0.00020482208,2.0,0.00020482208,0.055671666,0.4492841
Cleavage of Growing Transcript in the Termination Region ,2.2002525e-05,50.0,2.2002525e-05,-0.08102899,-1.8323882
Cleavage of the damaged purine,6.3677426e-08,2.0,6.3677426e-08,-0.09743344,0.33372173
Cleavage of the damaged pyrimidine ,0.00015245606,8.0,0.00015245606,0.016515743,0.14741807
"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00017361998,9.0,0.00017361998,0.03234075,0.11397739
Coenzyme A biosynthesis,2.8544156e-07,4.0,2.8544156e-07,-0.09726763,0.24307637
Cohesin Loading onto Chromatin,5.730766e-07,8.0,5.730766e-07,-0.097052544,0.061697733
Collagen chain trimerization,8.88844e-08,9.0,8.88844e-08,-0.0974146,0.01603921
Collagen degradation,2.2123254e-06,11.0,2.2123254e-06,-0.09582682,-0.07353285
Common Pathway of Fibrin Clot Formation,7.3753827e-06,5.0,7.3753827e-06,-0.09196623,0.20169257
Complex I biogenesis,6.342173e-07,24.0,6.342173e-07,-0.097006835,-0.6644317
Condensation of Prometaphase Chromosomes,4.156858e-10,5.0,4.156858e-10,-0.097480744,0.19753027
Condensation of Prophase Chromosomes,1.1303019e-06,13.0,1.1303019e-06,-0.09663589,-0.16491401
Conjugation of carboxylic acids,2.8002505e-11,2.0,2.8002505e-11,-0.097481035,0.3336858
Constitutive Signaling by AKT1 E17K in Cancer,0.00034493115,21.0,0.00034493115,0.16043618,-0.33396024
Constitutive Signaling by Aberrant PI3K in Cancer,1.2775071e-06,31.0,1.2775071e-06,-0.09652582,-0.98176533
Constitutive Signaling by EGFRvIII,2.283385e-05,13.0,2.283385e-05,-0.08040738,-0.15266487
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,3.499355e-05,16.0,3.499355e-05,-0.07131514,-0.28195786
Constitutive Signaling by NOTCH1 HD Domain Mutants,0.00042990057,11.0,0.00042990057,0.22397085,0.16784757
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,4.913193e-06,40.0,4.913193e-06,-0.09380729,-1.3881806
Constitutive Signaling by NOTCH1 PEST Domain Mutants,2.114666e-06,40.0,2.114666e-06,-0.09589984,-1.38976
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,2.6630952e-08,5.0,2.6630952e-08,-0.09746115,0.19754505
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,4.12361e-06,13.0,4.12361e-06,-0.094397694,-0.16322464
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,0.00051505276,21.0,0.00051505276,0.28764212,-0.23794633
Creatine metabolism,1.8213581e-05,5.0,1.8213581e-05,-0.08386212,0.2078095
Creation of C4 and C2 activators,4.0483646e-05,2.0,4.0483646e-05,-0.067210004,0.3565341
Cristae formation,1.1620714e-05,8.0,1.1620714e-05,-0.08879184,0.06793284
Cross-presentation of particulate exogenous antigens (phagosomes),7.8427924e-08,4.0,7.8427924e-08,-0.09742241,0.24295954
Cross-presentation of soluble exogenous antigens (endosomes),1.4070926e-07,28.0,1.4070926e-07,-0.09737585,-0.84625125
Crosslinking of collagen fibrils,1.2253132e-05,2.0,1.2253132e-05,-0.08831896,0.34060127
Cyclin A/B1/B2 associated events during G2/M transition,1.6136329e-07,11.0,1.6136329e-07,-0.0973604,-0.07469037
Cyclin D associated events in G1,5.922112e-07,32.0,5.922112e-07,-0.09703825,-1.0275373
Cysteine formation from homocysteine,1.1990368e-09,3.0,1.1990368e-09,-0.09748017,0.2883012
Cytochrome c-mediated apoptotic response,2.8515169e-07,6.0,2.8515169e-07,-0.097267844,0.1523057
Cytosolic iron-sulfur cluster assembly,7.580105e-08,8.0,7.580105e-08,-0.09742438,0.061417073
Cytosolic tRNA aminoacylation,2.958105e-06,18.0,2.958105e-06,-0.09526918,-0.39080864
DAP12 signaling,0.00034672848,21.0,0.00034672848,0.16178012,-0.33294585
DCC mediated attractive signaling,5.840491e-07,9.0,5.840491e-07,-0.09704434,0.016318675
DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,1.7377792e-05,7.0,1.7377792e-05,-0.084487066,0.1165673
DNA Damage Recognition in GG-NER,3.1608394e-07,21.0,3.1608394e-07,-0.09724471,-0.5284555
DNA methylation,0.0035376716,9.0,0.0035376716,2.5477614,2.0125942
DNA replication initiation,3.4408356e-05,6.0,3.4408356e-05,-0.07175271,0.1715643
DSCAM interactions,1.2751247e-08,7.0,1.2751247e-08,-0.09747153,0.10676674
Deactivation of the beta-catenin transactivating complex,3.9288734e-05,25.0,3.9288734e-05,-0.068103485,-0.6880009
Deadenylation of mRNA,2.0362835e-05,16.0,2.0362835e-05,-0.08225504,-0.2902152
Dectin-1 mediated noncanonical NF-kB signaling,1.3974064e-06,36.0,1.3974064e-06,-0.09643617,-1.2086239
Dectin-2 family,3.013158e-06,8.0,3.013158e-06,-0.09522801,0.06307487
Defective ABCA1 causes Tangier disease,0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B,0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2,0.0,1.0,0.0,-0.09748106,0.37907103
"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1",0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCC2 causes Dubin-Johnson syndrome,0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCC6 causes pseudoxanthoma elasticum (PXE),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCC8 can cause hypoglycemias and hyperglycemias,0.0,1.0,0.0,-0.09748106,0.37907103
"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia",0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCD1 causes adrenoleukodystrophy (ALD),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)",0.0,2.0,0.0,-0.09748106,0.3336858
Defective ABCG5 causes sitosterolemia,0.0,1.0,0.0,-0.09748106,0.37907103
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia,0.0,1.0,0.0,-0.09748106,0.37907103
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD),7.118935e-11,2.0,7.118935e-11,-0.097481005,0.33368582
Defective ACY1 causes encephalopathy,0.0,1.0,0.0,-0.09748106,0.37907103
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG1 causes ALG1-CDG (CDG-1k),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG11 causes ALG11-CDG (CDG-1p),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG12 causes ALG12-CDG (CDG-1g),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG2 causes ALG2-CDG (CDG-1i),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG3 causes ALG3-CDG (CDG-1d),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG6 causes ALG6-CDG (CDG-1c),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG8 causes ALG8-CDG (CDG-1h),0.0,1.0,0.0,-0.09748106,0.37907103
Defective ALG9 causes ALG9-CDG (CDG-1l),0.0,1.0,0.0,-0.09748106,0.37907103
Defective AMN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.09748106,0.37907103
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),7.3548667e-06,2.0,7.3548667e-06,-0.09198156,0.33783674
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),7.3548667e-06,2.0,7.3548667e-06,-0.09198156,0.33783674
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),7.4851814e-05,2.0,7.4851814e-05,-0.041511707,0.37593096
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),7.4851814e-05,2.0,7.4851814e-05,-0.041511707,0.37593096
Defective B3GALT6 causes EDSP2 and SEMDJL1,5.7441764e-07,4.0,5.7441764e-07,-0.097051546,0.24323946
Defective B3GALTL causes Peters-plus syndrome (PpS),2.1884587e-05,2.0,2.1884587e-05,-0.081117176,0.3460371
Defective B3GAT3 causes JDSSDHD,4.6006094e-06,4.0,4.6006094e-06,-0.09404103,0.24551177
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.09748106,0.37907103
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.09748106,0.37907103
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.09748106,0.37907103
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective B4GALT7 causes EDS, progeroid type",1.0339655e-06,4.0,1.0339655e-06,-0.096707925,0.24349883
Defective BTD causes biotidinase deficiency,0.0,1.0,0.0,-0.09748106,0.37907103
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),7.61812e-11,3.0,7.61812e-11,-0.097481005,0.28830057
Defective CD320 causes methylmalonic aciduria,0.0006319151,3.0,0.0006319151,0.37502426,0.64494336
Defective CFTR causes cystic fibrosis,0.00012211116,38.0,0.00012211116,-0.006174218,-1.2312654
"Defective CHST14 causes EDS, musculocontractural type",6.598143e-10,2.0,6.598143e-10,-0.09748057,0.33368614
Defective CHST3 causes SEDCJD,6.448286e-09,2.0,6.448286e-09,-0.09747624,0.33368942
Defective CHST6 causes MCDC1,0.0,1.0,0.0,-0.09748106,0.37907103
Defective CHSY1 causes TPBS,7.6273005e-05,2.0,7.6273005e-05,-0.04044903,0.37673306
Defective CP causes aceruloplasminemia (ACERULOP),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4),5.830465e-09,2.0,5.830465e-09,-0.0974767,0.3336891
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5),7.390205e-06,2.0,7.390205e-06,-0.09195514,0.33785668
Defective CUBN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.09748106,0.37907103
"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)",0.00026759406,3.0,0.00026759406,0.1026085,0.43932635
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP19A1 causes Aromatase excess syndrome (AEXS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP1B1 causes Glaucoma,0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A),0.0,1.0,0.0,-0.09748106,0.37907103
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",0.0,1.0,0.0,-0.09748106,0.37907103
"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",0.0,1.0,0.0,-0.09748106,0.37907103
"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective DHDDS causes retinitis pigmentosa 59,0.0,1.0,0.0,-0.09748106,0.37907103
Defective DOLK causes DOLK-CDG (CDG-1m),0.0,1.0,0.0,-0.09748106,0.37907103
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2,0.0,1.0,0.0,-0.09748106,0.37907103
Defective DPM1 causes DPM1-CDG (CDG-1e),0.0,1.0,0.0,-0.09748106,0.37907103
Defective DPM2 causes DPM2-CDG (CDG-1u),0.0,1.0,0.0,-0.09748106,0.37907103
Defective DPM3 causes DPM3-CDG (CDG-1o),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",0.00065357384,3.0,0.00065357384,0.39121926,0.65716714
Defective EXT2 causes exostoses 2,0.00020779153,3.0,0.00020779153,0.05789203,0.40557474
Defective FMO3 causes Trimethylaminuria (TMAU),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GALE can cause Epimerase-deficiency galactosemia (EDG),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GALK1 can cause Galactosemia II (GALCT2),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GALNT12 causes colorectal cancer 1 (CRCS1),2.341155e-10,3.0,2.341155e-10,-0.097480886,0.28830066
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),1.1039858e-06,3.0,1.1039858e-06,-0.09665557,0.2889236
Defective GALT can cause Galactosemia,0.0,1.0,0.0,-0.09748106,0.37907103
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GFPT1 causes CMSTA1,0.0,1.0,0.0,-0.09748106,0.37907103
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.09748106,0.37907103
Defective GIF causes intrinsic factor deficiency,0.0,1.0,0.0,-0.09748106,0.37907103
"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2",0.0,1.0,0.0,-0.09748106,0.37907103
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency),0.0,1.0,0.0,-0.09748106,0.37907103
Defective HEXA causes GM2G1,0.0,1.0,0.0,-0.09748106,0.37907103
Defective HEXB causes GM2G2,0.0,1.0,0.0,-0.09748106,0.37907103
Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,1.0,0.0,-0.09748106,0.37907103
Defective HLCS causes multiple carboxylase deficiency,0.00077912706,6.0,0.00077912706,0.48509985,0.5918717
Defective LARGE causes MDDGA6 and MDDGB6,0.0,1.0,0.0,-0.09748106,0.37907103
Defective LFNG causes SCDO3,1.1797776e-07,4.0,1.1797776e-07,-0.09739285,0.24298184
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF,0.0,1.0,0.0,-0.09748106,0.37907103
Defective MAN1B1 causes MRT15,0.0,1.0,0.0,-0.09748106,0.37907103
Defective MAOA causes Brunner syndrome (BRUNS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD),0.0,1.0,0.0,-0.09748106,0.37907103
Defective MGAT2 causes MGAT2-CDG (CDG-2a),0.0,1.0,0.0,-0.09748106,0.37907103
Defective MMAA causes methylmalonic aciduria type cblA,0.00012910969,2.0,0.00012910969,-0.00094117236,0.40655324
Defective MMAB causes methylmalonic aciduria type cblB,0.0,1.0,0.0,-0.09748106,0.37907103
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC,3.8720238e-05,2.0,3.8720238e-05,-0.06852856,0.35553885
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD,3.0292982e-05,3.0,3.0292982e-05,-0.07482992,0.3053974
Defective MOGS causes MOGS-CDG (CDG-2b),0.0,1.0,0.0,-0.09748106,0.37907103
Defective MPDU1 causes MPDU1-CDG (CDG-1f),0.0,1.0,0.0,-0.09748106,0.37907103
Defective MPI causes MPI-CDG (CDG-1b),0.0,1.0,0.0,-0.09748106,0.37907103
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG,2.122383e-05,3.0,2.122383e-05,-0.081611246,0.3002789
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE,8.550388e-05,3.0,8.550388e-05,-0.033546776,0.33655754
Defective MUT causes methylmalonic aciduria mut type,0.0,1.0,0.0,-0.09748106,0.37907103
Defective Mismatch Repair Associated With MLH1,1.8464964e-07,3.0,1.8464964e-07,-0.09734299,0.28840473
Defective Mismatch Repair Associated With MSH2,1.5010619e-07,3.0,1.5010619e-07,-0.09736882,0.28838524
Defective Mismatch Repair Associated With MSH3,2.8312265e-08,2.0,2.8312265e-08,-0.09745988,0.33370176
Defective Mismatch Repair Associated With MSH6,7.606046e-09,2.0,7.606046e-09,-0.097475365,0.33369008
Defective Mismatch Repair Associated With PMS2,2.464624e-08,3.0,2.464624e-08,-0.097462624,0.28831443
Defective NEU1 causes sialidosis,0.0,1.0,0.0,-0.09748106,0.37907103
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD),0.0,1.0,0.0,-0.09748106,0.37907103
Defective PAPSS2 causes SEMD-PA,0.0,1.0,0.0,-0.09748106,0.37907103
Defective PGM1 causes PGM1-CDG (CDG1t),0.0,1.0,0.0,-0.09748106,0.37907103
Defective PMM2 causes PMM2-CDG (CDG-1a),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",1.8326582e-12,2.0,1.8326582e-12,-0.09748106,0.3336858
"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",2.6141869e-09,2.0,2.6141869e-09,-0.0974791,0.33368725
"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",2.371678e-09,2.0,2.371678e-09,-0.097479284,0.33368713
Defective RFT1 causes RFT1-CDG (CDG-1n),0.0,1.0,0.0,-0.09748106,0.37907103
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC12A3 causes Gitelman syndrome (GS),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC26A2 causes chondrodysplasias,0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC26A4 causes Pendred syndrome (PDS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC3A1 causes cystinuria (CSNU),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A2 causes orthostatic intolerance (OI),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC7A9 causes cystinuria (CSNU),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SLC9A9 causes autism 16 (AUTS16),0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",2.451003e-06,2.0,2.451003e-06,-0.095648356,0.3350691
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",2.451003e-06,1.0,2.451003e-06,-0.095648356,0.38045433
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.09748106,0.3336858
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0,0.0,-0.09748106,0.37907103
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",1.1992348e-07,2.0,1.1992348e-07,-0.09739139,0.33375347
"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,1.0,0.0,-0.09748106,0.37907103
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ,0.0,1.0,0.0,-0.09748106,0.37907103
Defective ST3GAL3 causes MCT12 and EIEE15,0.0,1.0,0.0,-0.09748106,0.37907103
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD),0.0,1.0,0.0,-0.09748106,0.37907103
Defective TCN2 causes hereditary megaloblastic anemia,2.8261307e-05,2.0,2.8261307e-05,-0.07634908,0.34963602
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency),0.0,1.0,0.0,-0.09748106,0.37907103
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),0.0,1.0,0.0,-0.09748106,0.37907103
Defective UGT1A1 causes hyperbilirubinemia,0.0,1.0,0.0,-0.09748106,0.37907103
Defective UGT1A4 causes hyperbilirubinemia,0.0,1.0,0.0,-0.09748106,0.37907103
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS),3.2747743e-05,4.0,3.2747743e-05,-0.07299441,0.26139757
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS),6.639792e-05,2.0,6.639792e-05,-0.04783298,0.3711597
Degradation of AXIN,1.9669431e-05,34.0,1.9669431e-05,-0.08277353,-1.107541
Degradation of DVL,1.1962045e-05,35.0,1.1962045e-05,-0.08853661,-1.1572762
Degradation of GABA,2.0827336e-08,2.0,2.0827336e-08,-0.097465485,0.33369753
Degradation of GLI1 by the proteasome,0.00041495424,36.0,0.00041495424,0.21279494,-0.9752191
Degradation of GLI2 by the proteasome,0.00021077145,35.0,0.00021077145,0.060120225,-1.0450712
Deletions in the AMER1 gene destabilize the destruction complex,1.8086297e-09,2.0,1.8086297e-09,-0.09747971,0.3336868
Deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling,3.520551e-10,2.0,3.520551e-10,-0.0974808,0.33368596
Deposition of new CENPA-containing nucleosomes at the centromere,0.00016017884,20.0,0.00016017884,0.022290334,-0.3928463
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,1.3740753e-07,14.0,1.3740753e-07,-0.09737831,-0.21085961
Dermatan sulfate biosynthesis,4.0453047e-05,4.0,4.0453047e-05,-0.067232884,0.26574633
Detoxification of Reactive Oxygen Species,1.0817407e-05,12.0,1.0817407e-05,-0.0893925,-0.11406152
Digestion of dietary carbohydrate,8.827295e-06,5.0,8.827295e-06,-0.09088058,0.20251201
Digestion of dietary lipid,1.4807491e-12,3.0,1.4807491e-12,-0.09748106,0.2883005
Dimerization of procaspase-8,1.2947071e-05,8.0,1.2947071e-05,-0.08780008,0.06868141
Disassembly of the destruction complex and recruitment of AXIN to the membrane,1.0509493e-06,19.0,1.0509493e-06,-0.09669522,-0.43727025
Disinhibition of SNARE formation,6.5887906e-07,3.0,6.5887906e-07,-0.09698839,0.28867236
Displacement of DNA glycosylase by APEX1,5.234739e-08,8.0,5.234739e-08,-0.09744192,0.061403833
Dissolution of Fibrin Clot,6.644322e-08,3.0,6.644322e-08,-0.09743138,0.28833804
Dopamine Neurotransmitter Release Cycle,2.4716658e-07,7.0,2.4716658e-07,-0.097296245,0.10689904
Downregulation of ERBB2:ERBB3 signaling,4.5361537e-07,10.0,4.5361537e-07,-0.09714188,-0.02914019
Downregulation of ERBB4 signaling,1.3265125e-08,7.0,1.3265125e-08,-0.09747113,0.10676703
Downregulation of SMAD2/3:SMAD4 transcriptional activity,6.697284e-06,18.0,6.697284e-06,-0.09247326,-0.38869834
Downregulation of TGF-beta receptor signaling,1.0506216e-06,19.0,1.0506216e-06,-0.096695475,-0.43727043
Downstream TCR signaling,1.7703826e-07,56.0,1.7703826e-07,-0.09734868,-2.1170175
Downstream signal transduction,8.767452e-09,24.0,8.767452e-09,-0.09747451,-0.6647847
Downstream signaling of activated FGFR1,1.02281845e-07,14.0,1.02281845e-07,-0.09740458,-0.21087946
Downstream signaling of activated FGFR2,1.8790788e-06,14.0,1.8790788e-06,-0.09607601,-0.20987666
Downstream signaling of activated FGFR3,2.2576044e-06,14.0,2.2576044e-06,-0.09579297,-0.209663
Downstream signaling of activated FGFR4,1.1362243e-08,15.0,1.1362243e-08,-0.09747256,-0.256316
Dual Incision in GG-NER,5.8479924e-07,30.0,5.8479924e-07,-0.09704378,-0.93677104
Dual incision in TC-NER,2.1441772e-06,48.0,2.1441772e-06,-0.09587778,-1.7528253
E2F mediated regulation of DNA replication,1.592251e-08,15.0,1.592251e-08,-0.09746916,-0.2563134
E3 ubiquitin ligases ubiquitinate target proteins,2.9545072e-05,31.0,2.9545072e-05,-0.07538916,-0.9658116
ECM proteoglycans,3.1615955e-06,13.0,3.1615955e-06,-0.095117025,-0.16376758
EGFR downregulation,3.2589438e-07,17.0,3.2589438e-07,-0.09723738,-0.346909
EGFR interacts with phospholipase C-gamma,4.717121e-07,3.0,4.717121e-07,-0.09712834,0.28856677
EPH-ephrin mediated repulsion of cells,2.4080673e-06,28.0,2.4080673e-06,-0.09568046,-0.8449715
EPHA-mediated growth cone collapse,3.1659324e-06,10.0,3.1659324e-06,-0.095113784,-0.027609402
EPHB-mediated forward signaling,4.781232e-07,26.0,4.781232e-07,-0.097123556,-0.7552902
ER-Phagosome pathway,6.794554e-07,45.0,6.794554e-07,-0.096973,-1.6174964
ERBB2 Activates PTK6 Signaling,9.0251973e-07,6.0,9.0251973e-07,-0.09680621,0.15265414
ERBB2 Regulates Cell Motility,2.1542455e-06,7.0,2.1542455e-06,-0.09587025,0.10797537
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0007384198,17.0,0.0007384198,0.4546616,0.06965947
Early Phase of HIV Life Cycle,1.3124345e-07,7.0,1.3124345e-07,-0.097382925,0.106833614
Eicosanoid ligand-binding receptors,0.0,1.0,0.0,-0.09748106,0.37907103
Eicosanoids,8.897131e-10,2.0,8.897131e-10,-0.097480394,0.3336863
Electric Transmission Across Gap Junctions,2.1356868e-06,3.0,2.1356868e-06,-0.09588414,0.28950587
Electron transport from NADPH to Ferredoxin,1.5867005e-05,3.0,1.5867005e-05,-0.08561674,0.2972556
Elevation of cytosolic Ca2+ levels,2.7998555e-08,5.0,2.7998555e-08,-0.09746012,0.19754584
Endogenous sterols,1.3443751e-08,4.0,1.3443751e-08,-0.097471006,0.24292284
Endosomal Sorting Complex Required For Transport (ESCRT),0.0017868058,23.0,0.0017868058,1.2385769,0.3890403
Endosomal/Vacuolar pathway,5.067336e-06,7.0,5.067336e-06,-0.09369203,0.10961947
Energy dependent regulation of mTOR by LKB1-AMPK,9.056751e-06,23.0,9.056751e-06,-0.09070901,-0.6142929
Entry of Influenza Virion into Host Cell via Endocytosis,0.0,1.0,0.0,-0.09748106,0.37907103
Enzymatic degradation of Dopamine by monoamine oxidase,4.4987591e-10,2.0,4.4987591e-10,-0.09748072,0.33368602
Enzymatic degradation of dopamine by COMT,6.619775e-08,2.0,6.619775e-08,-0.09743156,0.33372313
Ephrin signaling,2.7515286e-08,12.0,2.7515286e-08,-0.097460486,-0.120151155
Erythrocytes take up carbon dioxide and release oxygen,0.00039738574,7.0,0.00039738574,0.19965833,0.33103773
Erythrocytes take up oxygen and release carbon dioxide,1.5733129e-07,4.0,1.5733129e-07,-0.09736341,0.24300407
Essential fructosuria,0.0,1.0,0.0,-0.09748106,0.37907103
Essential pentosuria,0.0,1.0,0.0,-0.09748106,0.37907103
Establishment of Sister Chromatid Cohesion,9.518903e-09,7.0,9.518903e-09,-0.09747394,0.10676491
Estrogen biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Estrogen-dependent gene expression,5.720326e-05,72.0,5.720326e-05,-0.054708157,-2.8109968
Ethanol oxidation,2.8590307e-06,5.0,2.8590307e-06,-0.09534326,0.19914362
Eukaryotic Translation Termination,0.00039575147,33.0,0.00039575147,0.19843635,-0.849901
Export of Viral Ribonucleoproteins from Nucleus,0.00030380773,3.0,0.00030380773,0.12968674,0.45976478
Extrinsic Pathway of Fibrin Clot Formation,1.6496228e-10,2.0,1.6496228e-10,-0.09748094,0.33368587
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,1.823742e-06,34.0,1.823742e-06,-0.09611738,-1.1176128
FCERI mediated Ca+2 mobilization,4.0218442e-08,18.0,4.0218442e-08,-0.09745099,-0.39245546
FCERI mediated MAPK activation,6.665192e-06,21.0,6.665192e-06,-0.09249725,-0.5248722
FCERI mediated NF-kB activation,2.272266e-06,53.0,2.272266e-06,-0.095782004,-1.9796791
FCGR activation,5.2867894e-05,7.0,5.2867894e-05,-0.05794986,0.13659734
FGFR1 ligand binding and activation,1.2638988e-07,3.0,1.2638988e-07,-0.09738656,0.28837183
FGFR1 mutant receptor activation,1.2135889e-05,17.0,1.2135889e-05,-0.08840662,-0.3402436
FGFR2 alternative splicing,4.9623045e-06,18.0,4.9623045e-06,-0.09377057,-0.3896775
FGFR2 ligand binding and activation,6.434506e-09,3.0,6.434506e-09,-0.09747625,0.28830415
FGFR2 mutant receptor activation,8.3583205e-07,14.0,8.3583205e-07,-0.09685608,-0.21046545
FGFR3 ligand binding and activation,6.089221e-08,3.0,6.089221e-08,-0.097435534,0.2883349
FGFR4 ligand binding and activation,1.6180161e-07,4.0,1.6180161e-07,-0.097360075,0.24300659
FGFR4 mutant receptor activation,0.0,1.0,0.0,-0.09748106,0.37907103
FGFRL1 modulation of FGFR1 signaling,2.5613081e-08,3.0,2.5613081e-08,-0.09746191,0.28831497
FMO oxidises nucleophiles,2.0335449e-11,2.0,2.0335449e-11,-0.09748105,0.3336858
Fanconi Anemia Pathway,3.6945483e-05,18.0,3.6945483e-05,-0.069855615,-0.3716267
FasL/ CD95L signaling,1.5219802e-08,4.0,1.5219802e-08,-0.09746968,0.24292386
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,3.303214e-08,6.0,3.303214e-08,-0.09745636,0.15216342
Fatty acids,6.2084116e-10,2.0,6.2084116e-10,-0.09748059,0.33368614
Fibronectin matrix formation,0.0,1.0,0.0,-0.09748106,0.37907103
Folding of actin by CCT/TriC,9.588538e-06,7.0,9.588538e-06,-0.09031137,0.112171166
Formation of ATP by chemiosmotic coupling,0.0,1.0,0.0,-0.09748106,0.37907103
Formation of Incision Complex in GG-NER,3.0700923e-07,33.0,3.0700923e-07,-0.09725149,-1.0730835
Formation of RNA Pol II elongation complex ,6.0427597e-06,42.0,6.0427597e-06,-0.092962675,-1.4783137
Formation of Senescence-Associated Heterochromatin Foci (SAHF),0.0012358865,7.0,0.0012358865,0.82663506,0.8042741
Formation of TC-NER Pre-Incision Complex,4.603313e-05,43.0,4.603313e-05,-0.063060455,-1.5011289
Formation of a pool of free 40S subunits,1.9039222e-05,41.0,1.9039222e-05,-0.083244756,-1.4255934
Formation of editosomes by ADAR proteins,4.3814688e-07,2.0,4.3814688e-07,-0.09715344,0.33393306
Formation of selenosugars for excretion,0.0,1.0,0.0,-0.09748106,0.37907103
Formation of the Early Elongation Complex,1.2645436e-05,26.0,1.2645436e-05,-0.088025615,-0.7484232
Formation of the Editosome,4.2357375e-09,3.0,4.2357375e-09,-0.09747789,0.2883029
"Formation of the active cofactor, UDP-glucuronate",0.0,1.0,0.0,-0.09748106,0.37907103
Formation of the cornified envelope,1.0714555e-05,21.0,1.0714555e-05,-0.08946941,-0.52258676
"Formation of the ternary complex, and subsequently, the 43S complex",1.8805036e-05,26.0,1.8805036e-05,-0.08341987,-0.74494684
Formation of tubulin folding intermediates by CCT/TriC,5.5854776e-05,11.0,5.5854776e-05,-0.055716462,-0.0432579
Formation of xylulose-5-phosphate,9.0761805e-06,3.0,9.0761805e-06,-0.09069447,0.29342297
Free fatty acid receptors,3.105566e-06,2.0,3.105566e-06,-0.09515891,0.33543852
Fructose biosynthesis,1.9388611e-07,3.0,1.9388611e-07,-0.09733608,0.28840995
Fructose catabolism,4.855853e-06,5.0,4.855853e-06,-0.093850166,0.2002706
Fusion and Uncoating of the Influenza Virion,0.0,1.0,0.0,-0.09748106,0.37907103
G alpha (12/13) signalling events,1.917822e-05,46.0,1.917822e-05,-0.08314083,-1.6524413
G alpha (z) signalling events,7.1601404e-05,17.0,7.1601404e-05,-0.043942153,-0.3066822
G beta:gamma signalling through PI3Kgamma,9.00403e-05,14.0,9.00403e-05,-0.030154733,-0.16011986
G beta:gamma signalling through PLC beta,4.7769525e-05,12.0,4.7769525e-05,-0.06176209,-0.09320633
G1/S-Specific Transcription,4.9560292e-08,8.0,4.9560292e-08,-0.097444,0.061402265
G2 Phase,4.64244e-08,3.0,4.64244e-08,-0.09744635,0.28832674
G2/M DNA replication checkpoint,1.9996734e-12,2.0,1.9996734e-12,-0.09748106,0.3336858
GAB1 signalosome,1.4016367e-06,8.0,1.4016367e-06,-0.096433006,0.062165357
GABA A (rho) receptor activation,0.0,1.0,0.0,-0.09748106,0.37907103
GABA A receptor activation,1.2375467e-08,3.0,1.2375467e-08,-0.09747181,0.2883075
GABA B receptor activation,7.33531e-07,16.0,7.33531e-07,-0.09693257,-0.30129367
GABA synthesis,0.0,1.0,0.0,-0.09748106,0.37907103
GLI proteins bind promoters of Hh responsive genes to promote transcription,7.576326e-09,2.0,7.576326e-09,-0.09747539,0.33369008
GLI3 is processed to GLI3R by the proteasome,0.0018366171,36.0,0.0018366171,1.2758226,-0.17285515
GP1b-IX-V activation signalling,1.6936501e-05,6.0,1.6936501e-05,-0.08481704,0.16170347
GPVI-mediated activation cascade,6.381003e-05,22.0,6.381003e-05,-0.049768038,-0.53800577
GRB2 events in EGFR signaling,2.1869482e-06,5.0,2.1869482e-06,-0.095845796,0.19876432
GRB2 events in ERBB2 signaling,2.5553616e-06,8.0,2.5553616e-06,-0.095570326,0.0628165
GRB2:SOS provides linkage to MAPK signaling for Integrins ,1.6399125e-06,7.0,1.6399125e-06,-0.09625484,0.10768508
GRB7 events in ERBB2 signaling,3.3560479e-09,4.0,3.3560479e-09,-0.097478546,0.24291718
GTP hydrolysis and joining of the 60S ribosomal subunit,0.00020534331,49.0,0.00020534331,0.056061413,-1.6835282
Galactose catabolism,6.188683e-06,5.0,6.188683e-06,-0.09285356,0.20102283
Gamma-carboxylation of protein precursors,0.0,1.0,0.0,-0.09748106,0.37907103
Gap junction assembly,0.00010851648,3.0,0.00010851648,-0.016339444,0.3495455
Gap junction degradation,0.0003023133,6.0,0.0003023133,0.1285693,0.3227656
Gap-filling DNA repair synthesis and ligation in GG-NER,6.509677e-09,18.0,6.509677e-09,-0.09747619,-0.39247447
Gap-filling DNA repair synthesis and ligation in TC-NER,8.3754713e-07,48.0,8.3754713e-07,-0.09685479,-1.7535627
Gastrin-CREB signalling pathway via PKC and MAPK,6.518566e-05,11.0,6.518566e-05,-0.04873943,-0.0379917
Generation of second messenger molecules,1.929278e-06,13.0,1.929278e-06,-0.09603847,-0.16446307
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,5.3406147e-08,16.0,5.3406147e-08,-0.09744113,-0.30167753
Glucagon-type ligand receptors,1.205289e-07,11.0,1.205289e-07,-0.097390935,-0.074713424
Glucocorticoid biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Gluconeogenesis,2.7976958e-07,20.0,2.7976958e-07,-0.09727186,-0.48309073
Glutamate Neurotransmitter Release Cycle,8.7598085e-07,8.0,8.7598085e-07,-0.096826054,0.06186868
Glutathione synthesis and recycling,7.401819e-07,6.0,7.401819e-07,-0.0969276,0.15256253
Glycerophospholipid catabolism,3.201295e-05,4.0,3.201295e-05,-0.07354385,0.26098284
Glycine degradation,1.4690964e-08,3.0,1.4690964e-08,-0.09747007,0.28830883
Glycogen breakdown (glycogenolysis),0.00011645669,13.0,0.00011645669,-0.010402263,-0.09982563
Glycogen storage disease type 0 (liver GYS2),0.0,1.0,0.0,-0.09748106,0.37907103
Glycogen storage disease type 0 (muscle GYS1),3.1711596e-05,3.0,3.1711596e-05,-0.073769175,0.30619806
Glycogen storage disease type II (GAA),0.00058975385,2.0,0.00058975385,0.3434988,0.66653347
Glycogen storage disease type IV (GBE1),0.0,1.0,0.0,-0.09748106,0.37907103
Glycogen storage disease type Ia (G6PC),0.0,1.0,0.0,-0.09748106,0.37907103
Glycogen storage disease type Ib (SLC37A4),0.0,1.0,0.0,-0.09748106,0.37907103
Glycogen storage disease type XV (GYG1),0.0005057081,3.0,0.0005057081,0.2806548,0.57371414
Glycogen synthesis,0.00034755265,10.0,0.00034755265,0.16239637,0.16675697
Glycoprotein hormones,0.0,1.0,0.0,-0.09748106,0.37907103
Glycosphingolipid metabolism,2.9475592e-05,20.0,2.9475592e-05,-0.075441115,-0.46661308
Golgi Associated Vesicle Biogenesis,1.0570724e-06,43.0,1.0570724e-06,-0.096690655,-1.5265126
Golgi Cisternae Pericentriolar Stack Reorganization,5.972631e-08,10.0,5.972631e-08,-0.097436406,-0.029362498
Growth hormone receptor signaling,0.00011057712,13.0,0.00011057712,-0.014798626,-0.10314397
HATs acetylate histones,9.1555574e-07,61.0,9.1555574e-07,-0.09679646,-2.343527
HCN channels,4.064247e-06,3.0,4.064247e-06,-0.09444208,0.29059434
HDACs deacetylate histones,1.7628783e-05,26.0,1.7628783e-05,-0.08429939,-0.7456107
HDL assembly,6.363413e-08,4.0,6.363413e-08,-0.09743348,0.24295118
HDL clearance,3.5966048e-05,3.0,3.5966048e-05,-0.07058797,0.30859917
HDL remodeling,4.0667317e-11,4.0,4.0667317e-11,-0.09748103,0.24291529
HDMs demethylate histones,1.2291652e-07,19.0,1.2291652e-07,-0.09738915,-0.43779403
HDR through Homologous Recombination (HRR),0.00029511363,42.0,0.00029511363,0.12318586,-1.3151667
HDR through MMEJ (alt-NHEJ),3.351891e-05,8.0,3.351891e-05,-0.07241778,0.08029183
HDR through Single Strand Annealing (SSA),0.00041201568,24.0,0.00041201568,0.21059768,-0.43225455
HHAT G278V abrogates palmitoylation of Hh-Np,0.0,1.0,0.0,-0.09748106,0.37907103
HS-GAG biosynthesis,0.0002558491,10.0,0.0002558491,0.093826376,0.11500095
HS-GAG degradation,4.078525e-06,6.0,4.078525e-06,-0.0944314,0.15444663
HSF1 activation,0.0016032726,11.0,0.0016032726,1.1013427,0.8300801
HSP90 chaperone cycle for steroid hormone receptors (SHR),2.3433319e-07,14.0,2.3433319e-07,-0.09730584,-0.21080492
Heme biosynthesis,0.0008399485,7.0,0.0008399485,0.5305782,0.5808131
Heme degradation,2.0046538e-05,3.0,2.0046538e-05,-0.082491554,0.29961446
Hereditary fructose intolerance,0.0,1.0,0.0,-0.09748106,0.37907103
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,8.4768384e-05,35.0,8.4768384e-05,-0.034096733,-1.1161853
Histidine catabolism,1.7894416e-07,5.0,1.7894416e-07,-0.09734725,0.19763102
Hormone ligand-binding receptors,6.8233027e-07,2.0,6.8233027e-07,-0.09697086,0.3340709
HuR (ELAVL1) binds and stabilizes mRNA,1.2657541e-05,8.0,1.2657541e-05,-0.08801657,0.068518005
Hyaluronan biosynthesis and export,0.0,1.0,0.0,-0.09748106,0.37907103
Hyaluronan uptake and degradation,8.7627114e-07,8.0,8.7627114e-07,-0.09682584,0.061868843
Hydrolysis of LPC,5.5851393e-07,4.0,5.5851393e-07,-0.09706344,0.24323049
Hydrolysis of LPE,2.412033e-06,2.0,2.412033e-06,-0.095677495,0.3350471
Hydroxycarboxylic acid-binding receptors,0.0,1.0,0.0,-0.09748106,0.37907103
Hypusine synthesis from eIF5A-lysine,1.5869072e-11,5.0,1.5869072e-11,-0.09748105,0.19753005
IKBKB deficiency causes SCID,4.609287e-06,2.0,4.609287e-06,-0.09403453,0.3362872
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),8.947519e-08,3.0,8.947519e-08,-0.09741415,0.28835103
IL-6-type cytokine receptor ligand interactions,1.3460884e-06,6.0,1.3460884e-06,-0.09647454,0.15290448
IP3 and IP4 transport between cytosol and nucleus,0.0,1.0,0.0,-0.09748106,0.37907103
IP6 and IP7 transport between cytosol and nucleus,0.0,1.0,0.0,-0.09748106,0.37907103
IPs transport between ER lumen and cytosol,0.0,1.0,0.0,-0.09748106,0.37907103
IPs transport between ER lumen and nucleus,0.0,1.0,0.0,-0.09748106,0.37907103
IPs transport between cytosol and ER lumen,0.0,1.0,0.0,-0.09748106,0.37907103
IPs transport between nucleus and ER lumen,0.0,1.0,0.0,-0.09748106,0.37907103
IPs transport between nucleus and cytosol,0.0,1.0,0.0,-0.09748106,0.37907103
IRAK4 deficiency (TLR2/4),1.2344552e-06,5.0,1.2344552e-06,-0.09655801,0.19822673
IRAK4 deficiency (TLR5),1.09338536e-07,4.0,1.09338536e-07,-0.0973993,0.24297698
IRF3 mediated activation of type 1 IFN,2.3585454e-08,3.0,2.3585454e-08,-0.09746342,0.28831384
IRF3-mediated induction of type I IFN,3.8918646e-05,3.0,3.8918646e-05,-0.06838021,0.3102656
IRS activation,7.485215e-07,3.0,7.485215e-07,-0.09692136,0.28872296
IRS-mediated signalling,0.0004422026,22.0,0.0004422026,0.2331695,-0.324447
ISG15 antiviral mechanism,0.00032376157,55.0,0.00032376157,0.14460695,-1.8890064
IkBA variant leads to EDA-ID,5.8505896e-07,7.0,5.8505896e-07,-0.09704359,0.10708975
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00024005705,27.0,0.00024005705,0.08201811,-0.665461
Import of palmitoyl-CoA into the mitochondrial matrix,0.00016579687,8.0,0.00016579687,0.026491133,0.1549474
Inactivation of APC/C via direct inhibition of the APC/C complex,2.963042e-07,14.0,2.963042e-07,-0.0972595,-0.21076994
Inactivation of CDC42 and RAC1,1.00621264e-07,5.0,1.00621264e-07,-0.09740581,0.19758683
Influenza Viral RNA Transcription and Replication,0.0006699146,53.0,0.0006699146,0.4034378,-1.6028725
Influenza Virus Induced Apoptosis,0.0,1.0,0.0,-0.09748106,0.37907103
Inhibition of Signaling by Overexpressed EGFR,6.3686787e-07,2.0,6.3686787e-07,-0.09700485,0.3340452
Inhibition of TSC complex formation by PKB,2.6599471e-08,3.0,2.6599471e-08,-0.09746117,0.28831553
InlA-mediated entry of Listeria monocytogenes into host cells,2.608517e-06,7.0,2.608517e-06,-0.09553058,0.10823175
InlB-mediated entry of Listeria monocytogenes into host cell,0.00063322607,12.0,0.00063322607,0.3760045,0.237216
Inositol transporters,2.7363964e-10,2.0,2.7363964e-10,-0.097480856,0.33368593
Insulin effects increased synthesis of Xylulose-5-Phosphate,3.7071608e-08,2.0,3.7071608e-08,-0.09745333,0.3337067
Insulin processing,3.835344e-07,17.0,3.835344e-07,-0.09719428,-0.34687644
Insulin receptor recycling,5.4175152e-06,14.0,5.4175152e-06,-0.09343019,-0.20787962
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,1.2523589e-06,6.0,1.2523589e-06,-0.09654463,0.15285158
Integrin cell surface interactions,1.47088385e-05,15.0,1.47088385e-05,-0.08648274,-0.24802099
Interaction With Cumulus Cells,0.0,1.0,0.0,-0.09748106,0.37907103
Interaction With The Zona Pellucida,1.6328827e-09,2.0,1.6328827e-09,-0.09747984,0.3336867
Interaction between L1 and Ankyrins,1.4302934e-09,7.0,1.4302934e-09,-0.09747999,0.106760345
Interaction between PHLDA1 and AURKA,0.0,1.0,0.0,-0.09748106,0.37907103
Interactions of Rev with host cellular proteins,1.6314467e-06,27.0,1.6314467e-06,-0.09626117,-0.80002457
Interactions of Tat with host cellular proteins,8.052063e-09,2.0,8.052063e-09,-0.097475044,0.33369032
Interactions of Vpr with host cellular proteins,1.08441974e-07,27.0,1.08441974e-07,-0.09739997,-0.8008842
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,4.942245e-07,4.0,4.942245e-07,-0.09711151,0.2431942
Interconversion of nucleotide di- and triphosphates,2.1218235e-05,12.0,2.1218235e-05,-0.08161543,-0.10819145
Interconversion of polyamines,0.0,1.0,0.0,-0.09748106,0.37907103
Interleukin receptor SHC signaling,0.00072574994,13.0,0.00072574994,0.44518787,0.24404977
Interleukin-1 processing,2.6580476e-05,2.0,2.6580476e-05,-0.077605896,0.34868738
Interleukin-10 signaling,9.046023e-07,5.0,9.046023e-07,-0.096804656,0.19804059
Interleukin-12 signaling,0.0018289288,23.0,0.0018289288,1.2700738,0.41281387
Interleukin-15 signaling,0.00058702775,9.0,0.00058702775,0.34146038,0.34729818
Interleukin-18 signaling,9.4301663e-07,2.0,9.4301663e-07,-0.09677593,0.334218
Interleukin-2 signaling,0.00022108048,8.0,0.00022108048,0.06782865,0.18614858
Interleukin-20 family signaling,0.0009261903,10.0,0.0009261903,0.5950642,0.49333087
Interleukin-21 signaling,7.822922e-05,6.0,7.822922e-05,-0.0389863,0.1962961
Interleukin-23 signaling,0.0008274064,4.0,0.0008274064,0.5212,0.70989025
Interleukin-27 signaling,0.00042326236,8.0,0.00042326236,0.2190072,0.30025682
Interleukin-33 signaling,8.3451243e-07,2.0,8.3451243e-07,-0.09685707,0.33415675
Interleukin-35 Signalling,0.00018771325,8.0,0.00018771325,0.042878788,0.16731666
Interleukin-36 pathway,5.4382308e-09,3.0,5.4382308e-09,-0.09747699,0.2883036
Interleukin-37 signaling,0.00059247273,15.0,0.00059247273,0.3455318,0.07805974
Interleukin-38 signaling,5.908733e-08,2.0,5.908733e-08,-0.09743688,0.3337191
Interleukin-4 and Interleukin-13 signaling,0.00012443542,43.0,0.00012443542,-0.0044362852,-1.45688
Interleukin-6 signaling,6.297811e-05,8.0,6.297811e-05,-0.05039009,0.09691814
Interleukin-7 signaling,0.008606762,14.0,0.008606762,6.3380995,4.646582
Interleukin-9 signaling,0.00023807352,6.0,0.00023807352,0.08053495,0.2865097
Intestinal hexose absorption,0.0,1.0,0.0,-0.09748106,0.37907103
Intestinal infectious diseases,0.0,1.0,0.0,-0.09748106,0.37907103
Intestinal lipid absorption,0.0,1.0,0.0,-0.09748106,0.37907103
Intestinal saccharidase deficiencies,0.0,1.0,0.0,-0.09748106,0.37907103
Intra-Golgi traffic,3.1251617e-05,29.0,3.1251617e-05,-0.074113116,-0.87407804
Intracellular oxygen transport,0.0,1.0,0.0,-0.09748106,0.37907103
Intraflagellar transport,1.1239111e-07,25.0,1.1239111e-07,-0.09739702,-0.71011144
Intrinsic Pathway of Fibrin Clot Formation,3.469394e-05,4.0,3.469394e-05,-0.07153917,0.26249596
Invadopodia formation,2.0951775e-05,4.0,2.0951775e-05,-0.08181468,0.2547401
Ion homeostasis,1.9811293e-09,12.0,1.9811293e-09,-0.09747958,-0.12016557
Ion influx/efflux at host-pathogen interface,6.8580855e-05,3.0,6.8580855e-05,-0.046200722,0.32700646
Ion transport by P-type ATPases,1.4511249e-05,18.0,1.4511249e-05,-0.086630486,-0.38428825
Ionotropic activity of kainate receptors,2.8154984e-06,4.0,2.8154984e-06,-0.095375806,0.24450429
Josephin domain DUBs,2.3103576e-07,6.0,2.3103576e-07,-0.0973083,0.15227517
KSRP (KHSRP) binds and destabilizes mRNA,1.8918712e-08,13.0,1.8918712e-08,-0.097466916,-0.16554126
Keratan sulfate biosynthesis,1.1591364e-05,10.0,1.1591364e-05,-0.08881378,-0.022854222
Keratan sulfate degradation,4.669535e-06,3.0,4.669535e-06,-0.093989484,0.29093593
Kinesins,0.0011890392,14.0,0.0011890392,0.79160565,0.46013758
L13a-mediated translational silencing of Ceruloplasmin expression,7.908924e-05,49.0,7.908924e-05,-0.038343232,-1.7547841
LDL clearance,3.836569e-06,12.0,3.836569e-06,-0.09461232,-0.118001394
LDL remodeling,0.0,1.0,0.0,-0.09748106,0.37907103
LGI-ADAM interactions,8.328686e-07,4.0,8.328686e-07,-0.0968583,0.24338531
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,3.0677504e-07,5.0,3.0677504e-07,-0.097251676,0.19770318
Lactose synthesis,7.526749e-08,3.0,7.526749e-08,-0.09742478,0.28834298
Laminin interactions,3.3846345e-06,7.0,3.3846345e-06,-0.09495025,0.10866977
Late Phase of HIV Life Cycle,7.2306227e-07,97.0,7.4542506e-09,-0.09747549,-3.9775047
Ligand-receptor interactions,0.0,1.0,0.0,-0.09748106,0.37907103
Linoleic acid (LA) metabolism,4.288654e-05,4.0,4.288654e-05,-0.065413274,0.26711974
Lipid particle organization,2.2755862e-07,3.0,2.2755862e-07,-0.0973109,0.28842896
Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,1.0,0.0,-0.09748106,0.37907103
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling,8.947371e-07,6.0,8.947371e-07,-0.09681203,0.15264975
Lysine catabolism,9.99394e-09,8.0,9.99394e-09,-0.097473584,0.061379932
Lysosomal oligosaccharide catabolism,1.0987419e-06,5.0,1.0987419e-06,-0.09665949,0.19815016
Lysosome Vesicle Biogenesis,7.164872e-08,22.0,7.164872e-08,-0.09742748,-0.5739787
Lysosphingolipid and LPA receptors,4.2729937e-07,6.0,4.2729937e-07,-0.09716155,0.15238594
MAP kinase activation,5.2156356e-05,46.0,5.2156356e-05,-0.058481902,-1.6338288
MAP2K and MAPK activation,7.0444557e-06,24.0,7.0444557e-06,-0.092213675,-0.66081387
MAPK1 (ERK2) activation,0.00020186743,3.0,0.00020186743,0.05346237,0.40223128
MAPK3 (ERK1) activation,0.0008131811,3.0,0.0008131811,0.51056325,0.74724704
MAPK6/MAPK4 signaling,2.2027536e-05,55.0,2.2027536e-05,-0.08101029,-2.0593002
MASTL Facilitates Mitotic Progression,8.767106e-08,8.0,8.767106e-08,-0.0974155,0.06142377
MET Receptor Activation,6.3558646e-12,2.0,6.3558646e-12,-0.09748106,0.3336858
MET activates PI3K/AKT signaling,1.0586841e-06,5.0,1.0586841e-06,-0.09668945,0.19812754
MET activates PTK2 signaling,9.668322e-09,4.0,9.668322e-09,-0.09747384,0.24292073
MET activates PTPN11,1.5079797e-06,4.0,1.5079797e-06,-0.096353486,0.24376635
MET activates RAP1 and RAC1,3.311821e-06,10.0,3.311821e-06,-0.095004685,-0.027527057
MET activates RAS signaling,7.0929923e-06,8.0,7.0929923e-06,-0.092177376,0.06537747
MET activates STAT3,1.1512538e-09,3.0,1.1512538e-09,-0.0974802,0.28830117
MET interacts with TNS proteins,2.305736e-09,2.0,2.305736e-09,-0.09747934,0.33368707
MET receptor recycling,7.56378e-10,6.0,7.56378e-10,-0.09748049,0.15214519
MGMT-mediated DNA damage reversal,1.0539263e-07,2.0,1.0539263e-07,-0.097402245,0.33374527
MHC class II antigen presentation,0.047371224,56.0,0.047371224,35.32366,24.618446
MPS I - Hurler syndrome,0.0,1.0,0.0,-0.09748106,0.37907103
MPS II - Hunter syndrome,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IIIA - Sanfilippo syndrome A,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IIIB - Sanfilippo syndrome B,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IIIC - Sanfilippo syndrome C,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IIID - Sanfilippo syndrome D,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IV - Morquio syndrome A,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IV - Morquio syndrome B,0.0,1.0,0.0,-0.09748106,0.37907103
MPS IX - Natowicz syndrome,0.0,1.0,0.0,-0.09748106,0.37907103
MPS VI - Maroteaux-Lamy syndrome,0.0,1.0,0.0,-0.09748106,0.37907103
MPS VII - Sly syndrome,0.0,1.0,0.0,-0.09748106,0.37907103
MTF1 activates gene expression,0.00016140912,3.0,0.00016140912,0.023210257,0.37939724
Macroautophagy,2.9882201e-05,42.0,2.9882201e-05,-0.07513708,-1.464859
Major pathway of rRNA processing in the nucleolus and cytosol,0.00040618572,88.0,0.00040618572,0.2062384,-3.340201
Meiotic recombination,0.0010373355,20.0,0.0010373355,0.67817146,0.10220696
Meiotic synapsis,3.3445963e-06,24.0,3.3445963e-06,-0.09498019,-0.662902
Melanin biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Metabolism of Angiotensinogen to Angiotensins,5.3023354e-07,3.0,5.3023354e-07,-0.09708459,0.28859976
Metabolism of folate and pterines,1.8092159e-07,10.0,1.8092159e-07,-0.09734578,-0.02929409
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,1.2033877e-06,4.0,1.2033877e-06,-0.09658124,0.24359442
Metabolism of ingested MeSeO2H into MeSeH,9.987481e-08,2.0,9.987481e-08,-0.09740638,0.33374214
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",9.40818e-06,6.0,9.40818e-06,-0.090446234,0.1574546
Metabolism of serotonin,1.9986799e-09,2.0,1.9986799e-09,-0.09747957,0.3336869
Metabolism of vitamin K,1.0307107e-07,3.0,1.0307107e-07,-0.09740399,0.2883587
Metal sequestration by antimicrobial proteins,0.0,1.0,0.0,-0.09748106,0.37907103
Metalloprotease DUBs,3.717935e-05,17.0,3.717935e-05,-0.06968074,-0.32610947
Metallothioneins bind metals,0.0,1.0,0.0,-0.09748106,0.37907103
Methionine salvage pathway,2.7898895e-06,6.0,2.7898895e-06,-0.095394954,0.15371935
Methylation,1.1426004e-06,9.0,1.1426004e-06,-0.09662669,0.016633907
Methylation of MeSeH for excretion,0.0,1.0,0.0,-0.09748106,0.37907103
MicroRNA (miRNA) biogenesis,0.0007135167,16.0,0.0007135167,0.43604067,0.10098979
Mineralocorticoid biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Miscellaneous substrates,5.6912014e-10,3.0,5.6912014e-10,-0.09748063,0.28830084
Miscellaneous transport and binding events,8.878779e-07,15.0,8.878779e-07,-0.09681716,-0.25582132
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),9.143003e-06,10.0,9.143003e-06,-0.09064451,-0.02423604
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),1.247289e-07,11.0,1.247289e-07,-0.0973878,-0.074711055
Misspliced GSK3beta mutants stabilize beta-catenin,7.201068e-07,11.0,7.201068e-07,-0.09694261,-0.07437503
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling,1.3159834e-09,3.0,1.3159834e-09,-0.09748008,0.28830126
Mitochondrial ABC transporters,1.5507413e-10,4.0,1.5507413e-10,-0.09748094,0.24291535
Mitochondrial protein import,0.00012485823,36.0,0.00012485823,-0.0041201385,-1.1389446
Mitochondrial tRNA aminoacylation,1.4956516e-05,15.0,1.4956516e-05,-0.08629754,-0.2478812
Mitochondrial transcription initiation,8.742419e-06,3.0,8.742419e-06,-0.090944044,0.2932346
Mitochondrial transcription termination,3.0533047e-05,2.0,3.0533047e-05,-0.074650414,0.35091814
Mitochondrial translation elongation,2.053503e-05,50.0,2.053503e-05,-0.08212629,-1.8332163
Mitochondrial translation initiation,0.00037486988,50.0,0.00037486988,0.18282245,-1.6332353
Mitochondrial translation termination,0.00019938702,50.0,0.00019938702,0.051607683,-1.7322751
Mitotic Anaphase,7.231897e-07,104.0,6.9537474e-09,-0.09747586,-4.2952013
Mitotic Metaphase/Anaphase Transition,4.7563134e-08,2.0,4.7563134e-08,-0.09744549,0.3337126
Molecules associated with elastic fibres,0.000107984444,11.0,0.000107984444,-0.016737264,-0.013836749
Molybdenum cofactor biosynthesis,0.00011239464,4.0,0.00011239464,-0.013439602,0.306349
Mtb iron assimilation by chelation,0.0,1.0,0.0,-0.09748106,0.37907103
Multifunctional anion exchangers,6.532362e-09,2.0,6.532362e-09,-0.09747618,0.33368945
MyD88 deficiency (TLR2/4),1.397062e-05,4.0,1.397062e-05,-0.08703473,0.25080007
MyD88 deficiency (TLR5),2.7001097e-06,2.0,2.7001097e-06,-0.09546209,0.33520967
MyD88 dependent cascade initiated on endosome,0.00016449965,54.0,0.00016449965,0.02552116,-1.9335059
MyD88-independent TLR4 cascade ,4.7846684e-06,63.0,4.7846684e-06,-0.09390339,-2.4321136
Myoclonic epilepsy of Lafora,0.0045507737,7.0,0.0045507737,3.3052936,2.6751435
N-glycan antennae elongation in the medial/trans-Golgi,6.8885865e-06,12.0,6.8885865e-06,-0.09233022,-0.11627889
N-glycan trimming and elongation in the cis-Golgi,1.2247635e-05,4.0,1.2247635e-05,-0.08832307,0.24982764
NADE modulates death signalling,2.4052963e-07,5.0,2.4052963e-07,-0.09730121,0.19766578
NADPH regeneration,1.6684072e-09,2.0,1.6684072e-09,-0.097479805,0.3336867
NCAM1 interactions,2.866495e-10,13.0,2.866495e-10,-0.09748084,-0.16555178
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,0.00017056604,10.0,0.00017056604,0.030057212,0.06686855
NF-kB is activated and signals survival,4.691292e-06,11.0,4.691292e-06,-0.09397321,-0.07213376
NFG and proNGF binds to p75NTR,1.8809547e-09,2.0,1.8809547e-09,-0.09747966,0.33368683
NGF processing,9.986179e-07,3.0,9.986179e-07,-0.09673435,0.28886414
NIK-->noncanonical NF-kB signaling,0.00065012556,36.0,0.00065012556,0.38864085,-0.8424921
NOD1/2 Signaling Pathway,0.00026175915,25.0,0.00026175915,0.09824554,-0.5624422
NOSIP mediated eNOS trafficking,0.0,1.0,0.0,-0.09748106,0.37907103
NOSTRIN mediated eNOS trafficking,5.9207352e-05,4.0,5.9207352e-05,-0.053209625,0.27633095
NOTCH1 Intracellular Domain Regulates Transcription,0.0005910352,31.0,0.0005910352,0.34445688,-0.6489155
NOTCH2 Activation and Transmission of Signal to the Nucleus,1.2706504e-06,16.0,1.2706504e-06,-0.09653095,-0.30099055
NOTCH2 intracellular domain regulates transcription,1.0009267e-05,8.0,1.0009267e-05,-0.08999678,0.06702336
NOTCH3 Intracellular Domain Regulates Transcription,1.6052047e-06,15.0,1.6052047e-06,-0.09628079,-0.25541645
NOTCH4 Activation and Transmission of Signal to the Nucleus,4.0742572e-07,8.0,4.0742572e-07,-0.09717641,0.06160424
NOTCH4 Intracellular Domain Regulates Transcription,9.490384e-06,9.0,9.490384e-06,-0.09038477,0.02134526
NR1D1 (REV-ERBA) represses gene expression,9.326278e-06,3.0,9.326278e-06,-0.09050747,0.29356414
NRAGE signals death through JNK,7.876133e-06,32.0,7.876133e-06,-0.09159179,-1.0234264
NRIF signals cell death from the nucleus,1.7893906e-06,13.0,1.7893906e-06,-0.09614307,-0.16454203
NS1 Mediated Effects on Host Pathways,0.0006991464,29.0,0.0006991464,0.42529547,-0.49712878
NTF3 activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.09748106,0.37907103
NTF3 activates NTRK3 signaling,0.0,1.0,0.0,-0.09748106,0.37907103
NTF4 activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.09748106,0.37907103
NTRK3 as a dependence receptor,9.681035e-08,3.0,9.681035e-08,-0.09740867,0.28835517
Na+/Cl- dependent neurotransmitter transporters,7.5880816e-06,4.0,7.5880816e-06,-0.09180718,0.24719785
Nectin/Necl  trans heterodimerization,9.380588e-08,2.0,9.380588e-08,-0.09741092,0.3337387
Neddylation,9.5152484e-07,141.0,6.748403e-09,-0.09747601,-5.974326
Negative regulation of FGFR1 signaling,1.4501923e-07,18.0,1.4501923e-07,-0.09737262,-0.39239633
Negative regulation of FGFR2 signaling,1.8929319e-05,18.0,1.8929319e-05,-0.083326936,-0.38179475
Negative regulation of FGFR3 signaling,8.102125e-05,18.0,8.102125e-05,-0.036898598,-0.34675106
Negative regulation of FGFR4 signaling,2.0407004e-05,19.0,2.0407004e-05,-0.08222202,-0.426346
Negative regulation of MAPK pathway,3.6328674e-05,25.0,3.6328674e-05,-0.07031682,-0.6896715
Negative regulation of MET activity,3.0599327e-05,17.0,3.0599327e-05,-0.07460085,-0.32982314
Negative regulation of NOTCH4 signaling,1.2882379e-05,35.0,1.2882379e-05,-0.08784845,-1.1567566
Negative regulation of TCF-dependent signaling by DVL-interacting proteins,2.2622166e-07,4.0,2.2622166e-07,-0.09731191,0.24304295
Negative regulation of TCF-dependent signaling by WNT ligand antagonists,2.429442e-06,4.0,2.429442e-06,-0.09566448,0.2442864
Negative regulation of activity of TFAP2 (AP-2) family transcription factors,9.764744e-08,6.0,9.764744e-08,-0.09740805,0.1521999
Negative regulators of DDX58/IFIH1 signaling,0.0034330976,28.0,0.0034330976,2.4695678,1.0912548
Nephrin family interactions,1.9646726e-05,12.0,1.9646726e-05,-0.0827905,-0.10907839
Netrin mediated repulsion signals,1.8885603e-10,4.0,1.8885603e-10,-0.097480915,0.24291538
Neurexins and neuroligins,2.5441523e-05,17.0,2.5441523e-05,-0.078457534,-0.3327341
Neurofascin interactions,5.7266757e-08,4.0,5.7266757e-08,-0.097438246,0.2429476
Neurophilin interactions with VEGF and VEGFR,0.0,1.0,0.0,-0.09748106,0.37907103
Neutrophil degranulation,0.00011254354,239.0,4.7089347e-07,-0.09712895,-10.359099
Nicotinamide salvaging,5.661757e-05,7.0,5.661757e-05,-0.055146094,0.1387136
NoRC negatively regulates rRNA expression,1.2667655e-05,40.0,1.2667655e-05,-0.08800901,-1.3838041
Noncanonical activation of NOTCH3,4.95522e-10,6.0,4.95522e-10,-0.09748069,0.15214506
Nonhomologous End-Joining (NHEJ),0.0016076422,25.0,0.0016076422,1.10461,0.19715266
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),0.0011567656,51.0,0.0011567656,0.7674736,-1.2373313
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),3.4174099e-07,36.0,3.4174099e-07,-0.09722553,-1.2092197
Norepinephrine Neurotransmitter Release Cycle,8.866025e-10,6.0,8.866025e-10,-0.097480394,0.15214528
Notch-HLH transcription pathway,9.696985e-07,12.0,9.696985e-07,-0.09675598,-0.1196194
NrCAM interactions,5.9399985e-11,4.0,5.9399985e-11,-0.09748101,0.2429153
Nuclear Envelope Breakdown,1.4554845e-06,33.0,1.4554845e-06,-0.09639274,-1.0724354
Nuclear Events (kinase and transcription factor activation),5.4171902e-05,19.0,5.4171902e-05,-0.056974806,-0.40728962
Nuclear Receptor transcription pathway,9.272939e-06,28.0,9.272939e-06,-0.09054735,-0.84109706
Nuclear signaling by ERBB4,0.0001298976,13.0,0.0001298976,-0.00035202154,-0.092239805
Nucleotide-like (purinergic) receptors,3.0424474e-07,4.0,3.0424474e-07,-0.09725356,0.243087
O-glycosylation of TSR domain-containing proteins,3.5350804e-05,3.0,3.5350804e-05,-0.07104801,0.30825195
Olfactory Signaling Pathway,1.101345e-06,36.0,1.101345e-06,-0.096657544,-1.208791
Oncogene Induced Senescence,0.00043442773,23.0,0.00043442773,0.22735596,-0.3742203
Opioid Signalling,0.00043609305,41.0,0.00043609305,0.22860117,-1.1902149
Opsins,1.048648e-06,3.0,1.048648e-06,-0.09669694,0.28889236
Orc1 removal from chromatin,8.959649e-06,46.0,8.959649e-06,-0.090781614,-1.6582084
Organic anion transport,2.1091577e-10,2.0,2.1091577e-10,-0.09748091,0.33368587
Organic anion transporters,5.6085508e-08,2.0,5.6085508e-08,-0.097439125,0.33371744
Organic cation transport,6.649635e-10,2.0,6.649635e-10,-0.09748056,0.33368614
Other interleukin signaling,0.0004967023,14.0,0.0004967023,0.27392086,0.0693937
Other semaphorin interactions,3.3333623e-09,6.0,3.3333623e-09,-0.09747857,0.15214667
Ovarian tumor domain proteases,0.00066813274,25.0,0.00066813274,0.40210545,-0.3330914
Oxidative Stress Induced Senescence,0.0026760697,47.0,0.0026760697,1.903511,-0.19831917
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha,1.2933131e-05,3.0,1.2933131e-05,-0.0878105,0.2955998
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0020182156,37.0,0.0020182156,1.4116102,-0.115749225
PAOs oxidise polyamines to amines,0.0,1.0,0.0,-0.09748106,0.37907103
PCNA-Dependent Long Patch Base Excision Repair,9.850953e-05,15.0,9.850953e-05,-0.023821991,-0.2007252
PD-1 signaling,8.763566e-06,6.0,8.763566e-06,-0.090928234,0.1570908
PECAM1 interactions,5.2083345e-07,10.0,5.2083345e-07,-0.097091615,-0.029102251
PI and PC transport between ER and Golgi membranes,1.0542374e-06,3.0,1.0542374e-06,-0.09669276,0.28889552
PI3K events in ERBB2 signaling,3.3789863e-08,8.0,3.3789863e-08,-0.09745579,0.061393358
PI3K events in ERBB4 signaling,1.9360156e-08,5.0,1.9360156e-08,-0.09746659,0.19754095
PI3K/AKT activation,2.1552573e-06,7.0,2.1552573e-06,-0.0958695,0.107975945
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",1.2164983e-06,46.0,1.2164983e-06,-0.09657144,-1.6625785
PIPs transport between Golgi and plasma membranes,0.0,1.0,0.0,-0.09748106,0.37907103
PIPs transport between early and late endosome membranes,0.0,1.0,0.0,-0.09748106,0.37907103
PIPs transport between early endosome and Golgi membranes,0.0,1.0,0.0,-0.09748106,0.37907103
PIPs transport between late endosome and Golgi membranes,0.0,1.0,0.0,-0.09748106,0.37907103
PIPs transport between plasma and early endosome membranes,0.0,1.0,0.0,-0.09748106,0.37907103
PIWI-interacting RNA (piRNA) biogenesis,0.00034221774,12.0,0.00034221774,0.15840727,0.072975546
PKA activation in glucagon signalling,1.0222786e-05,7.0,1.0222786e-05,-0.08983712,0.11252913
PKA-mediated phosphorylation of key metabolic factors,2.5698915e-13,2.0,2.5698915e-13,-0.09748106,0.3336858
PKMTs methylate histone lysines,6.023773e-06,32.0,6.023773e-06,-0.09297687,-1.0244719
PLC-gamma1 signalling,2.8215803e-07,2.0,2.8215803e-07,-0.09727008,0.33384502
PLCG1 events in ERBB2 signaling,3.7157604e-09,4.0,3.7157604e-09,-0.097478285,0.24291736
POLB-Dependent Long Patch Base Excision Repair,8.606204e-06,7.0,8.606204e-06,-0.091045894,0.111616746
"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",4.275497e-07,4.0,4.275497e-07,-0.09716137,0.24315655
"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",4.1953672e-07,3.0,4.1953672e-07,-0.09716736,0.2885373
PP2A-mediated dephosphorylation of key metabolic factors,1.750983e-09,5.0,1.750983e-09,-0.09747975,0.19753101
PPARA activates gene expression,0.00031768176,20.0,0.00031768176,0.14006084,-0.30395412
PRC2 methylates histones and DNA,0.00037090268,19.0,0.00037090268,0.17985602,-0.22853184
PTEN Loss of Function in Cancer,0.0,1.0,0.0,-0.09748106,0.37907103
PTK6 Activates STAT3,2.6993656e-09,3.0,2.6993656e-09,-0.097479045,0.28830203
PTK6 Down-Regulation,9.235872e-06,3.0,9.235872e-06,-0.09057507,0.29351312
PTK6 Expression,1.7117862e-09,5.0,1.7117862e-09,-0.097479776,0.197531
PTK6 Regulates Cell Cycle,4.5005627e-06,7.0,4.5005627e-06,-0.09411583,0.109299585
PTK6 Regulates Proteins Involved in RNA Processing,1.016478e-06,4.0,1.016478e-06,-0.096721,0.24348895
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",2.9067382e-06,11.0,2.9067382e-06,-0.09530758,-0.07314093
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,1.0803094e-05,9.0,1.0803094e-05,-0.089403205,0.022086136
PTK6 promotes HIF1A stabilization,5.145295e-08,4.0,5.145295e-08,-0.09744258,0.2429443
Packaging Of Telomere Ends,3.8083685e-06,12.0,3.8083685e-06,-0.09463341,-0.1180173
Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00032419394,23.0,0.00032419394,0.14493024,-0.4364345
Passive transport by Aquaporins,3.023338e-05,3.0,3.023338e-05,-0.07487449,0.30536374
Peptide chain elongation,2.934195e-05,32.0,2.934195e-05,-0.07554104,-1.0113114
Peptide ligand-binding receptors,1.13826545e-05,31.0,1.13826545e-05,-0.08896985,-0.9760622
Phase 0 - rapid depolarisation,9.995315e-07,10.0,9.995315e-07,-0.096733674,-0.028832084
Phase 1 - inactivation of fast Na+ channels,7.9882045e-07,5.0,7.9882045e-07,-0.096883744,0.19798088
Phase 2 - plateau phase,1.4138917e-05,11.0,1.4138917e-05,-0.08690889,-0.06680167
Phase 3 - rapid repolarisation,5.1208253e-06,4.0,5.1208253e-06,-0.09365204,0.24580538
Phase 4 - resting membrane potential,5.6220124e-06,5.0,5.6220124e-06,-0.093277276,0.20070301
Phenylalanine and tyrosine catabolism,2.7365616e-08,5.0,2.7365616e-08,-0.09746059,0.19754548
Phenylketonuria,0.0,1.0,0.0,-0.09748106,0.37907103
Phosphate bond hydrolysis by NTPDase proteins,2.1044875e-07,5.0,2.1044875e-07,-0.0973237,0.1976488
Phosphate bond hydrolysis by NUDT proteins,7.557592e-05,6.0,7.557592e-05,-0.040970266,0.19479862
Phosphorylation of CD3 and TCR zeta chains,9.337054e-07,6.0,9.337054e-07,-0.09678289,0.15267175
Physiological factors,3.3728538e-06,2.0,3.3728538e-06,-0.09495905,0.33558938
Pink/Parkin Mediated Mitophagy,1.8212802e-06,16.0,1.8212802e-06,-0.096119225,-0.3006798
Plasmalogen biosynthesis,3.433448e-08,3.0,3.433448e-08,-0.09745539,0.2883199
Platelet Adhesion to exposed collagen,7.4565874e-06,7.0,7.4565874e-06,-0.091905504,0.110967934
Platelet degranulation ,0.00013342219,54.0,0.00013342219,0.0022834395,-1.9510455
Platelet sensitization by LDL,9.499335e-06,10.0,9.499335e-06,-0.09037807,-0.024034927
Polo-like kinase mediated events,1.3990037e-06,7.0,1.3990037e-06,-0.09643497,0.10754912
Polymerase switching,1.7134964e-05,11.0,1.7134964e-05,-0.08466864,-0.06511074
Post NMDA receptor activation events,4.017203e-05,17.0,4.017203e-05,-0.067443006,-0.32442045
Post-chaperonin tubulin folding pathway,5.7831035e-06,7.0,5.7831035e-06,-0.09315683,0.11002344
Post-transcriptional silencing by small RNAs,5.569617e-06,7.0,5.569617e-06,-0.09331646,0.10990294
Post-translational protein phosphorylation,1.24278895e-05,36.0,1.24278895e-05,-0.08818828,-1.2023985
Potassium transport channels,1.4011756e-07,3.0,1.4011756e-07,-0.09737629,0.2883796
Pre-NOTCH Processing in Golgi,3.549126e-06,7.0,3.549126e-06,-0.09482725,0.108762614
Pre-NOTCH Processing in the Endoplasmic Reticulum,3.498064e-06,6.0,3.498064e-06,-0.094865434,0.15411903
Pre-NOTCH Transcription and Translation,1.3323581e-05,34.0,1.3323581e-05,-0.08751854,-1.1111225
Prefoldin mediated transfer of substrate  to CCT/TriC,7.5242056e-06,14.0,7.5242056e-06,-0.09185495,-0.20669064
Pregnenolone biosynthesis,4.1215532e-07,6.0,4.1215532e-07,-0.09717288,0.15237738
Presynaptic depolarization and calcium channel opening,1.5852014e-07,7.0,1.5852014e-07,-0.09736253,0.106849
Presynaptic function of Kainate receptors,9.020867e-06,12.0,9.020867e-06,-0.09073584,-0.11507546
Processing of DNA double-strand break ends,0.0010634183,44.0,0.0010634183,0.6976745,-0.9723182
Processing of Intronless Pre-mRNAs,2.4100507e-06,14.0,2.4100507e-06,-0.095678985,-0.20957698
Processing of SMDT1,2.759945e-05,9.0,2.759945e-05,-0.07684397,0.031565733
Processive synthesis on the lagging strand,0.0005600021,11.0,0.0005600021,0.32125235,0.24127482
Prolactin receptor signaling,4.3235746e-06,9.0,4.3235746e-06,-0.09424817,0.0184292
Proline catabolism,0.0,1.0,0.0,-0.09748106,0.37907103
Propionyl-CoA catabolism,0.00014093514,5.0,0.00014093514,0.007901139,0.27707157
Prostacyclin signalling through prostacyclin receptor,4.604971e-05,11.0,4.604971e-05,-0.06304806,-0.04879173
Protein methylation,1.1501311e-07,8.0,1.1501311e-07,-0.097395055,0.061439205
Protein repair,1.947682e-05,4.0,1.947682e-05,-0.08291755,0.25390768
Proton-coupled monocarboxylate transport,1.7052653e-09,2.0,1.7052653e-09,-0.09747978,0.33368674
Proton-coupled neutral amino acid transporters,0.0,1.0,0.0,-0.09748106,0.37907103
Proton/oligopeptide cotransporters,2.9602043e-10,2.0,2.9602043e-10,-0.09748084,0.33368593
Purine ribonucleoside monophosphate biosynthesis,7.607459e-08,10.0,7.607459e-08,-0.09742417,-0.029353263
Purine salvage,3.0726245e-05,8.0,3.0726245e-05,-0.074505955,0.07871569
Pyrimidine biosynthesis,1.9241097e-07,2.0,1.9241097e-07,-0.097337194,0.3337944
Pyrimidine catabolism,2.8848768e-07,3.0,2.8848768e-07,-0.09726534,0.28846332
Pyrimidine salvage,7.2097514e-06,6.0,7.2097514e-06,-0.09209008,0.15621383
Pyrophosphate hydrolysis,3.6950328e-11,2.0,3.6950328e-11,-0.09748103,0.3336858
RA biosynthesis pathway,7.408072e-07,10.0,7.408072e-07,-0.09692713,-0.0289781
RAB GEFs exchange GTP for GDP on RABs,0.0018698375,63.0,0.0018698375,1.3006628,-1.3795077
RAB geranylgeranylation,0.0004100282,42.0,0.0004100282,0.20911156,-1.2503107
RAF activation,7.5768116e-07,18.0,7.5768116e-07,-0.09691452,-0.39205056
RAS signaling downstream of NF1 loss-of-function variants,1.7952643e-05,5.0,1.7952643e-05,-0.084057234,0.20766221
RET signaling,1.2506152e-06,20.0,1.2506152e-06,-0.09654593,-0.4825428
RHO GTPases Activate Formins,3.3026643e-06,66.0,3.3026643e-06,-0.09501155,-2.569106
RHO GTPases Activate NADPH Oxidases,3.561279e-05,5.0,3.561279e-05,-0.070852116,0.21762933
RHO GTPases Activate ROCKs,6.493276e-05,11.0,6.493276e-05,-0.048928533,-0.03813443
RHO GTPases Activate Rhotekin and Rhophilins,1.1790369e-08,6.0,1.1790369e-08,-0.09747224,0.15215144
RHO GTPases Activate WASPs and WAVEs,0.00073733804,29.0,0.00073733804,0.4538527,-0.47557402
RHO GTPases activate CIT,0.00018129969,9.0,0.00018129969,0.038083147,0.118311696
RHO GTPases activate IQGAPs,8.742175e-06,11.0,8.742175e-06,-0.09094423,-0.0698475
RHO GTPases activate KTN1,2.1554986e-06,10.0,2.1554986e-06,-0.09586931,-0.028179672
RHO GTPases activate PAKs,2.1960243e-05,13.0,2.1960243e-05,-0.0810606,-0.15315792
RHO GTPases regulate CFTR trafficking,2.9806296e-07,2.0,2.9806296e-07,-0.09725818,0.333854
RIP-mediated NFkB activation via ZBP1,1.3593591e-05,10.0,1.3593591e-05,-0.08731665,-0.021724194
RMTs methylate histone arginines,5.5150704e-06,27.0,5.5150704e-06,-0.09335724,-0.7978328
RNA Pol II CTD phosphorylation and interaction with CE,8.752922e-05,21.0,8.752922e-05,-0.032032363,-0.47923377
RNA Polymerase I Chain Elongation,8.626084e-08,19.0,8.626084e-08,-0.09741656,-0.4378147
RNA Polymerase I Promoter Escape,2.19386e-07,19.0,2.19386e-07,-0.09731702,-0.43773958
RNA Polymerase I Promoter Opening,8.2884155e-10,3.0,8.2884155e-10,-0.09748044,0.288301
RNA Polymerase I Transcription Initiation,4.2772562e-08,21.0,4.2772562e-08,-0.09744908,-0.52860975
RNA Polymerase I Transcription Termination,2.1223727e-07,20.0,2.1223727e-07,-0.09732236,-0.48312885
RNA Polymerase II Pre-transcription Events,6.448812e-05,59.0,6.448812e-05,-0.049261004,-2.2168772
RNA Polymerase II Promoter Escape,4.7866964e-05,35.0,4.7866964e-05,-0.06168923,-1.137012
RNA Polymerase II Transcription Initiation,8.5589573e-07,35.0,8.5589573e-07,-0.096841075,-1.1635443
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,7.379769e-06,35.0,7.379769e-06,-0.09196294,-1.1598623
RNA Polymerase III Abortive And Retractive Initiation,3.739807e-05,26.0,3.739807e-05,-0.069517195,-0.7344532
RNA Polymerase III Chain Elongation,1.2556179e-06,14.0,1.2556179e-06,-0.096542194,-0.21022853
RNA Polymerase III Transcription Initiation From Type 1 Promoter,6.272468e-05,21.0,6.272468e-05,-0.050579596,-0.49323308
RNA Polymerase III Transcription Initiation From Type 2 Promoter,3.2533295e-05,21.0,3.2533295e-05,-0.07315476,-0.5102726
RNA Polymerase III Transcription Initiation From Type 3 Promoter,1.7073795e-06,20.0,1.7073795e-06,-0.09620439,-0.48228502
RNA Polymerase III Transcription Termination,1.8490778e-07,14.0,1.8490778e-07,-0.0973428,-0.21083282
RNA polymerase II transcribes snRNA genes,5.53888e-06,47.0,5.53888e-06,-0.09333944,-1.7055241
RNF mutants show enhanced WNT signaling and proliferation,9.857241e-09,2.0,9.857241e-09,-0.097473696,0.33369133
ROBO receptors bind AKAP5,8.592209e-09,4.0,8.592209e-09,-0.09747464,0.2429201
RORA activates gene expression,0.0014003686,4.0,0.0014003686,0.9496242,1.0332611
"ROS, RNS production in phagocytes",1.345348e-05,14.0,1.345348e-05,-0.08742142,-0.20334426
RPIA deficiency: failed conversion of R5P to RU5P,0.0,1.0,0.0,-0.09748106,0.37907103
RPIA deficiency: failed conversion of RU5P to R5P,0.0,1.0,0.0,-0.09748106,0.37907103
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),1.1028477e-06,3.0,1.1028477e-06,-0.09665642,0.28892297
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,0.0001390076,25.0,0.0001390076,0.0064598545,-0.6317212
RUNX1 regulates estrogen receptor mediated transcription,7.433207e-07,7.0,7.433207e-07,-0.09692525,0.10717907
RUNX1 regulates expression of components of tight junctions,6.3918133e-06,4.0,6.3918133e-06,-0.09270167,0.2465227
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,0.0019463232,33.0,0.0019463232,1.3578538,0.025216881
RUNX1 regulates transcription of genes involved in BCR signaling,1.3128164e-06,5.0,1.3128164e-06,-0.09649942,0.19827098
RUNX1 regulates transcription of genes involved in WNT signaling,6.5869716e-07,5.0,6.5869716e-07,-0.09698853,0.19790179
RUNX1 regulates transcription of genes involved in differentiation of HSCs,0.0021545314,50.0,0.0021545314,1.5135385,-0.62882286
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,2.4936708e-05,6.0,2.4936708e-05,-0.078834996,0.16621865
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,4.566088e-05,6.0,4.566088e-05,-0.0633388,0.17791505
RUNX1 regulates transcription of genes involved in interleukin signaling,3.1722064e-07,4.0,3.1722064e-07,-0.09724387,0.24309431
RUNX2 regulates bone development,6.9456975e-05,16.0,6.9456975e-05,-0.04554562,-0.26250726
RUNX2 regulates genes involved in cell migration,1.1713535e-05,6.0,1.1713535e-05,-0.08872243,0.15875572
RUNX2 regulates genes involved in differentiation of myeloid cells,1.405099e-06,4.0,1.405099e-06,-0.09643041,0.24370828
RUNX3 Regulates Immune Response and Cell Migration,8.391164e-08,3.0,8.391164e-08,-0.097418316,0.28834787
RUNX3 regulates BCL2L11 (BIM) transcription,3.4004532e-07,4.0,3.4004532e-07,-0.09722679,0.2431072
RUNX3 regulates CDKN1A transcription,5.578437e-05,6.0,5.578437e-05,-0.055769105,0.18362859
RUNX3 regulates NOTCH signaling,1.2742137e-05,11.0,1.2742137e-05,-0.087953314,-0.06758998
RUNX3 regulates RUNX1-mediated transcription,5.068594e-07,3.0,5.068594e-07,-0.09710206,0.2885866
RUNX3 regulates WNT signaling,0.00013875577,7.0,0.00013875577,0.006271548,0.18507108
RUNX3 regulates YAP1-mediated transcription,3.3279787e-06,2.0,3.3279787e-06,-0.09499261,0.33556405
RUNX3 regulates p14-ARF,8.260711e-07,5.0,8.260711e-07,-0.09686338,0.19799626
Rap1 signalling,1.2659847e-06,8.0,1.2659847e-06,-0.09653444,0.062088795
Receptor Mediated Mitophagy,0.0034543974,10.0,0.0034543974,2.4854944,1.9202107
Receptor-type tyrosine-protein phosphatases,4.0550512e-05,7.0,4.0550512e-05,-0.06716,0.1296456
Recognition and association of DNA glycosylase with site containing an affected purine,1.661288e-08,2.0,1.661288e-08,-0.09746863,0.33369514
Recognition and association of DNA glycosylase with site containing an affected pyrimidine,7.779661e-08,8.0,7.779661e-08,-0.09742289,0.061418198
Recognition of DNA damage by PCNA-containing replication complex,0.00022727434,22.0,0.00022727434,0.07246002,-0.44574907
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,1.2650309e-05,30.0,1.2650309e-05,-0.08802198,-0.92996144
Recruitment of NuMA to mitotic centrosomes,3.3526266e-09,55.0,3.3526266e-09,-0.09747855,-2.0717304
Recycling of bile acids and salts,2.294633e-07,5.0,2.294633e-07,-0.09730948,0.19765955
Recycling of eIF2:GDP,0.000105258536,8.0,0.000105258536,-0.018775523,0.120780535
Recycling pathway of L1,6.832338e-09,18.0,6.832338e-09,-0.097475946,-0.3924743
Reduction of cytosolic Ca++ levels,3.5773305e-06,4.0,3.5773305e-06,-0.094806165,0.24493426
Reelin signalling pathway,1.184611e-10,3.0,1.184611e-10,-0.097480975,0.28830057
Regulated proteolysis of p75NTR,1.7119555e-06,10.0,1.7119555e-06,-0.096200965,-0.028429996
Regulation by TREX1,0.0,1.0,0.0,-0.09748106,0.37907103
Regulation by c-FLIP,4.7935824e-05,9.0,4.7935824e-05,-0.06163774,0.04304326
Regulation of Complement cascade,0.00092856114,7.0,0.00092856114,0.596837,0.6308246
Regulation of FZD by ubiquitination,2.2778391e-05,8.0,2.2778391e-05,-0.08044885,0.07423005
Regulation of Glucokinase by Glucokinase Regulatory Protein,1.3181722e-06,23.0,1.3181722e-06,-0.09649542,-0.61866045
Regulation of HSF1-mediated heat shock response,0.00024393678,45.0,0.00024393678,0.08491912,-1.4802058
Regulation of IFNA signaling,0.0006698548,10.0,0.0006698548,0.40339312,0.34865916
Regulation of IFNG signaling,3.667576e-05,11.0,3.667576e-05,-0.070057295,-0.054082233
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00039497486,36.0,0.00039497486,0.19785565,-0.986495
Regulation of KIT signaling,7.8701676e-05,12.0,7.8701676e-05,-0.038633026,-0.07574872
Regulation of PAK-2p34 activity by PS-GAP/RHG10,2.749734e-07,3.0,2.749734e-07,-0.09727545,0.28845572
Regulation of PLK1 Activity at G2/M Transition,1.6654532e-05,59.0,1.6654532e-05,-0.08502787,-2.2438736
Regulation of PTEN gene transcription,9.1717175e-06,36.0,9.1717175e-06,-0.09062304,-1.2042361
Regulation of PTEN localization,1.5728843e-07,8.0,1.5728843e-07,-0.09736345,0.061463065
Regulation of PTEN mRNA translation,0.00012668715,10.0,0.00012668715,-0.002752584,0.042104006
Regulation of PTEN stability and activity,1.9658031e-05,44.0,1.9658031e-05,-0.08278205,-1.5613998
Regulation of RAS by GAPs,9.119566e-07,42.0,9.119566e-07,-0.09679916,-1.4812094
Regulation of RUNX1 Expression and Activity,0.0009734037,17.0,0.0009734037,0.63036734,0.20228061
Regulation of RUNX2 expression and activity,0.0005127448,42.0,0.0005127448,0.28591642,-1.1923391
Regulation of RUNX3 expression and activity,1.3815713e-05,32.0,1.3815713e-05,-0.08715056,-1.0200741
Regulation of TLR by endogenous ligand,4.862971e-05,5.0,4.862971e-05,-0.061118905,0.22497585
Regulation of TNFR1 signaling,3.226062e-07,22.0,3.226062e-07,-0.09723984,-0.57383704
Regulation of TP53 Activity,7.782035e-05,110.0,7.074577e-07,-0.096952066,-4.524
Regulation of actin dynamics for phagocytic cup formation,0.00063681474,42.0,0.00063681474,0.3786879,-1.1223159
Regulation of activated PAK-2p34 by proteasome mediated degradation,2.4229037e-06,31.0,2.4229037e-06,-0.09566937,-0.98111886
Regulation of commissural axon pathfinding by SLIT and ROBO,4.0390646e-11,2.0,4.0390646e-11,-0.09748103,0.3336858
Regulation of cortical dendrite branching,0.0,1.0,0.0,-0.09748106,0.37907103
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,3.7638056e-05,6.0,3.7638056e-05,-0.06933775,0.17338708
Regulation of expression of SLITs and ROBOs,1.4557686e-06,76.0,1.4557686e-06,-0.09639253,-3.024001
Regulation of gene expression by Hypoxia-inducible Factor,0.0028812862,7.0,0.0028812862,2.0569587,1.7329113
Regulation of gene expression in early pancreatic precursor cells,0.0,1.0,0.0,-0.09748106,0.37907103
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,0.0,1.0,0.0,-0.09748106,0.37907103
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,1.8167825e-08,2.0,1.8167825e-08,-0.09746748,0.33369604
Regulation of ornithine decarboxylase (ODC),9.08974e-06,31.0,9.08974e-06,-0.09068434,-0.97735626
Regulation of pyruvate dehydrogenase (PDH) complex,4.0985697e-06,9.0,4.0985697e-06,-0.09441641,0.018302212
Regulation of signaling by CBL,5.691004e-06,17.0,5.691004e-06,-0.093225695,-0.343881
Regulation of signaling by NODAL,2.729334e-05,3.0,2.729334e-05,-0.07707286,0.30370444
Regulation of thyroid hormone activity,5.5561924e-09,2.0,5.5561924e-09,-0.0974769,0.3336889
Release of Hh-Np from the secreting cell,1.2897359e-05,3.0,1.2897359e-05,-0.08783724,0.2955796
Release of apoptotic factors from the mitochondria,2.3574619e-06,3.0,2.3574619e-06,-0.095718294,0.28963104
Removal of aminoterminal propeptides from gamma-carboxylated proteins,1.1741196e-05,2.0,1.1741196e-05,-0.08870175,0.34031233
Repression of WNT target genes,8.30481e-08,8.0,8.30481e-08,-0.097418964,0.061421163
Resolution of Sister Chromatid Cohesion,5.404918e-09,57.0,5.404918e-09,-0.09747702,-2.1625
Retinoid metabolism and transport,5.6815303e-08,13.0,5.6815303e-08,-0.09743858,-0.16551988
Retinoid metabolism disease events,0.0,1.0,0.0,-0.09748106,0.37907103
Retrograde neurotrophin signalling,3.3393508e-06,9.0,3.3393508e-06,-0.094984114,0.017873716
Retrograde transport at the Trans-Golgi-Network,1.6567986e-06,40.0,1.6567986e-06,-0.09624222,-1.3900185
Reuptake of GABA,0.0,1.0,0.0,-0.09748106,0.37907103
Reversible hydration of carbon dioxide,1.3024683e-08,4.0,1.3024683e-08,-0.09747132,0.24292262
Rhesus glycoproteins mediate ammonium transport.,3.2255437e-10,2.0,3.2255437e-10,-0.09748082,0.33368596
Rho GTPase cycle,1.3536408e-07,67.0,1.3536408e-07,-0.09737984,-2.616279
Ribosomal scanning and start codon recognition,0.0011006302,31.0,0.0011006302,0.7254991,-0.36130828
Role of ABL in ROBO-SLIT signaling,1.3394666e-07,5.0,1.3394666e-07,-0.0973809,0.19760564
Role of LAT2/NTAL/LAB on calcium mobilization,6.0687795e-05,11.0,6.0687795e-05,-0.052102644,-0.04053022
Role of phospholipids in phagocytosis,1.8121647e-05,14.0,1.8121647e-05,-0.083930865,-0.20070961
Role of second messengers in netrin-1 signaling,2.165947e-10,4.0,2.165947e-10,-0.09748089,0.24291539
S33 mutants of beta-catenin aren't phosphorylated,2.8416386e-07,11.0,2.8416386e-07,-0.097268574,-0.07462107
S37 mutants of beta-catenin aren't phosphorylated,2.4759568e-06,11.0,2.4759568e-06,-0.09562971,-0.07338406
S45 mutants of beta-catenin aren't phosphorylated,1.4219605e-05,11.0,1.4219605e-05,-0.08684856,-0.06675613
SCF(Skp2)-mediated degradation of p27/p21,1.3322698e-08,38.0,1.3322698e-08,-0.097471096,-1.3001755
SDK interactions,0.0,1.0,0.0,-0.09748106,0.37907103
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,1.2255138e-06,7.0,1.2255138e-06,-0.096564695,0.10745121
SHC-related events triggered by IGF1R,7.827153e-06,5.0,7.827153e-06,-0.09162842,0.20194754
SHC1 events in EGFR signaling,4.7734677e-05,6.0,4.7734677e-05,-0.06178815,0.17908546
SHC1 events in ERBB2 signaling,2.6308579e-05,12.0,2.6308579e-05,-0.0778092,-0.105318554
SHC1 events in ERBB4 signaling,2.8419845e-06,7.0,2.8419845e-06,-0.095356,0.10836351
SIRT1 negatively regulates rRNA expression,6.2746203e-06,13.0,6.2746203e-06,-0.0927893,-0.16201064
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,1.2618843e-07,7.0,1.2618843e-07,-0.097386695,0.10683077
SLBP independent Processing of Histone Pre-mRNAs,7.87123e-08,7.0,7.87123e-08,-0.097422205,0.10680397
SLIT2:ROBO1 increases RHOA activity,4.216626e-08,2.0,4.216626e-08,-0.097449526,0.33370957
SMAC-mediated apoptotic response,1.2033069e-06,6.0,1.2033069e-06,-0.0965813,0.15282391
SMAD2/3 MH2 Domain Mutants in Cancer,8.310209e-07,6.0,8.310209e-07,-0.09685968,0.15261379
SMAD2/3 Phosphorylation Motif Mutants in Cancer,1.8613208e-07,5.0,1.8613208e-07,-0.09734188,0.19763507
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,2.3203103e-05,22.0,2.3203103e-05,-0.08013128,-0.56092364
SMAD4 MH2 Domain Mutants in Cancer,7.637622e-07,4.0,7.637622e-07,-0.09690997,0.2433463
SRP-dependent cotranslational protein targeting to membrane,1.6749769e-06,49.0,1.6749769e-06,-0.096228614,-1.7984754
STAT6-mediated induction of chemokines,1.1679255e-07,3.0,1.1679255e-07,-0.09739373,0.28836644
SUMO is conjugated to E1 (UBA2:SAE1),9.054991e-06,4.0,9.054991e-06,-0.09071033,0.24802576
SUMO is proteolytically processed,3.485135e-06,6.0,3.485135e-06,-0.0948751,0.15411173
"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",1.6860598e-05,5.0,1.6860598e-05,-0.084873796,0.20704588
SUMOylation of DNA damage response and repair proteins,0.0001748518,51.0,0.0001748518,0.033261824,-1.7915078
SUMOylation of DNA methylation proteins,7.81136e-05,9.0,7.81136e-05,-0.039072756,0.060075108
SUMOylation of DNA replication proteins,2.330091e-05,32.0,2.330091e-05,-0.08005814,-1.0147209
SUMOylation of RNA binding proteins,7.364587e-05,33.0,7.364587e-05,-0.042413432,-1.0316923
SUMOylation of SUMOylation proteins,4.284245e-05,28.0,4.284245e-05,-0.065446235,-0.822151
SUMOylation of chromatin organization proteins,0.0011909736,38.0,0.0011909736,0.7930521,-0.6280166
SUMOylation of immune response proteins,1.8070496e-06,11.0,1.8070496e-06,-0.09612987,-0.07376158
SUMOylation of intracellular receptors,2.2379547e-06,21.0,2.2379547e-06,-0.095807664,-0.5273708
SUMOylation of transcription cofactors,5.5167442e-05,32.0,5.5167442e-05,-0.056230403,-0.99673593
SUMOylation of transcription factors,3.772612e-05,16.0,3.772612e-05,-0.06927191,-0.28041565
SUMOylation of ubiquitinylation proteins,1.8616955e-06,31.0,1.8616955e-06,-0.096089,-0.98143566
Scavenging by Class A Receptors,9.945492e-06,7.0,9.945492e-06,-0.09004446,0.11237263
Scavenging by Class B Receptors,2.4930216e-08,3.0,2.4930216e-08,-0.09746242,0.2883146
Scavenging by Class F Receptors,3.7889845e-06,5.0,3.7889845e-06,-0.0946479,0.19966847
Scavenging by Class H Receptors,1.5206269e-05,2.0,1.5206269e-05,-0.08611079,0.34226796
Scavenging of heme from plasma,3.5688018e-07,6.0,3.5688018e-07,-0.0972142,0.1523462
SeMet incorporation into proteins,1.4797156e-06,8.0,1.4797156e-06,-0.09637462,0.062209416
Selenocysteine synthesis,2.1674072e-05,35.0,2.1674072e-05,-0.081274584,-1.1517948
Sema3A PAK dependent Axon repulsion,4.8975664e-07,9.0,4.8975664e-07,-0.097114846,0.016265454
Sema4D induced cell migration and growth-cone collapse,1.5539004e-07,11.0,1.5539004e-07,-0.09736487,-0.07469375
Sema4D mediated inhibition of cell attachment and migration,6.127667e-07,5.0,6.127667e-07,-0.09702287,0.19787587
Senescence-Associated Secretory Phenotype (SASP),4.69077e-05,35.0,4.69077e-05,-0.06240651,-1.1375533
Sensing of DNA Double Strand Breaks,1.4023004e-06,4.0,1.4023004e-06,-0.096432514,0.24370669
Serine biosynthesis,5.354804e-05,6.0,5.354804e-05,-0.057441294,0.18236643
Serotonin Neurotransmitter Release Cycle,1.7266942e-08,6.0,1.7266942e-08,-0.097468145,0.15215452
Serotonin and melatonin biosynthesis,0.0,1.0,0.0,-0.09748106,0.37907103
Severe congenital neutropenia type 4 (G6PC3),0.0,1.0,0.0,-0.09748106,0.37907103
Signal attenuation,1.9911835e-07,6.0,1.9911835e-07,-0.09733217,0.15225714
Signal regulatory protein family interactions,4.3047086e-07,8.0,4.3047086e-07,-0.09715918,0.061617244
Signal transduction by L1,2.8874254e-07,13.0,2.8874254e-07,-0.09726516,-0.16538897
Signaling by BMP,9.257859e-06,13.0,9.257859e-06,-0.09055863,-0.16032694
Signaling by BRAF and RAF fusions,0.0006354663,36.0,0.0006354663,0.37767962,-0.8507655
Signaling by FGFR3 fusions in cancer,5.866452e-06,9.0,5.866452e-06,-0.09309451,0.019299971
Signaling by FGFR3 point mutants in cancer,4.608577e-05,11.0,4.608577e-05,-0.06302109,-0.048771374
Signaling by Hippo,2.5697686e-06,10.0,2.5697686e-06,-0.09555955,-0.027945867
Signaling by Leptin,1.1608475e-06,10.0,1.1608475e-06,-0.09661305,-0.028741037
Signaling by MST1,0.0,1.0,0.0,-0.09748106,0.37907103
Signaling by RAS mutants,2.105023e-05,29.0,2.105023e-05,-0.08174106,-0.8798355
Signaling by high-kinase activity BRAF mutants,0.00041275183,17.0,0.00041275183,0.21114813,-0.11414236
Signaling by moderate kinase activity BRAF mutants,5.4239918e-05,23.0,5.4239918e-05,-0.05692395,-0.58879226
Signalling to ERK5,1.8597198e-06,3.0,1.8597198e-06,-0.09609048,0.28935012
Signalling to ERKs,6.210964e-05,20.0,6.210964e-05,-0.05103948,-0.44819495
Signalling to STAT3,7.709695e-06,2.0,7.709695e-06,-0.09171625,0.338037
Small interfering RNA (siRNA) biogenesis,9.771186e-05,6.0,9.771186e-05,-0.024418438,0.2072918
Smooth Muscle Contraction,0.0002192975,17.0,0.0002192975,0.06649545,-0.2233249
"Sodium-coupled sulphate, di- and tri-carboxylate transporters",9.7987545e-08,3.0,9.7987545e-08,-0.09740779,0.28835583
Sodium/Calcium exchangers,1.2419143e-06,5.0,1.2419143e-06,-0.09655243,0.19823095
Sodium/Proton exchangers,8.173331e-06,9.0,8.173331e-06,-0.09136957,0.020601938
Sperm Motility And Taxes,1.0684598e-05,2.0,1.0684598e-05,-0.08949181,0.339716
Sperm:Oocyte Membrane Binding,3.4458686e-11,2.0,3.4458686e-11,-0.097481035,0.3336858
Sphingolipid de novo biosynthesis,1.7274797e-05,20.0,1.7274797e-05,-0.08456408,-0.47349903
Stimulation of the cell death response by PAK-2p34,1.60612e-09,3.0,1.60612e-09,-0.097479865,0.2883014
Striated Muscle Contraction,8.210482e-05,18.0,8.210482e-05,-0.036088374,-0.34613952
Sulfide oxidation to sulfate,8.3355586e-11,2.0,8.3355586e-11,-0.097481,0.33368585
Surfactant metabolism,1.9656225e-05,9.0,1.9656225e-05,-0.0827834,0.027082706
Synaptic adhesion-like molecules,7.117502e-05,12.0,7.117502e-05,-0.044260975,-0.07999665
Syndecan interactions,1.8613768e-07,9.0,1.8613768e-07,-0.09734188,0.016094094
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),9.930938e-06,2.0,9.930938e-06,-0.09005535,0.33929065
Synthesis of 12-eicosatetraenoic acid derivatives,3.73488e-05,3.0,3.73488e-05,-0.06955404,0.30937958
Synthesis of 15-eicosatetraenoic acid derivatives,1.4599724e-05,2.0,1.4599724e-05,-0.086564325,0.34192562
Synthesis of 5-eicosatetraenoic acids,0.00023951895,4.0,0.00023951895,0.081615746,0.37809595
Synthesis of BMP,0.0,1.0,0.0,-0.09748106,0.37907103
Synthesis of CL,1.2631454e-05,2.0,1.2631454e-05,-0.088036075,0.34081477
Synthesis of Hepoxilins (HX) and Trioxilins (TrX),4.5695197e-06,2.0,4.5695197e-06,-0.094064265,0.33626476
"Synthesis of IP2, IP, and Ins in the cytosol",9.357629e-06,9.0,9.357629e-06,-0.09048402,0.02127034
Synthesis of IP3 and IP4 in the cytosol,0.0001661728,15.0,0.0001661728,0.026772233,-0.16253714
Synthesis of IPs in the ER lumen,0.0,1.0,0.0,-0.09748106,0.37907103
Synthesis of IPs in the nucleus,3.5757714e-07,3.0,3.5757714e-07,-0.09721368,0.28850234
Synthesis of Ketone Bodies,7.727588e-07,4.0,7.727588e-07,-0.096903235,0.2433514
Synthesis of Leukotrienes (LT) and Eoxins (EX),3.2366064e-05,5.0,3.2366064e-05,-0.073279805,0.21579692
Synthesis of Lipoxins (LX),1.0540788e-06,3.0,1.0540788e-06,-0.09669288,0.28889543
Synthesis of PA,0.000106490406,15.0,0.000106490406,-0.01785441,-0.19622093
Synthesis of PC,0.00023910418,16.0,0.00023910418,0.08130561,-0.1667611
Synthesis of PE,3.472243e-05,9.0,3.472243e-05,-0.07151787,0.035585824
Synthesis of PG,2.3820423e-05,7.0,2.3820423e-05,-0.079669684,0.12020341
Synthesis of PI,2.5766987e-08,3.0,2.5766987e-08,-0.09746179,0.2883151
Synthesis of PIPs at the ER membrane,0.00056070654,6.0,0.00056070654,0.32177907,0.46859857
Synthesis of PIPs at the Golgi membrane,1.930398e-07,12.0,1.930398e-07,-0.09733671,-0.12005774
Synthesis of PIPs at the early endosome membrane,0.0006068064,14.0,0.0006068064,0.3562496,0.1315347
Synthesis of PIPs at the late endosome membrane,6.340339e-05,9.0,6.340339e-05,-0.050072096,0.051772907
Synthesis of PIPs at the plasma membrane,0.0028875493,39.0,0.0028875493,2.061642,0.28411853
Synthesis of PIPs in the nucleus,5.545112e-05,4.0,5.545112e-05,-0.056018293,0.274211
Synthesis of PS,0.0,1.0,0.0,-0.09748106,0.37907103
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),4.515034e-05,5.0,4.515034e-05,-0.06372055,0.22301216
Synthesis of active ubiquitin: roles of E1 and E2 enzymes,0.00017275283,22.0,0.00017275283,0.031692352,-0.47652018
Synthesis of bile acids and bile salts,7.1249076e-08,7.0,7.1249076e-08,-0.097427785,0.10679975
Synthesis of diphthamide-EEF2,9.5991346e-08,7.0,9.5991346e-08,-0.097409286,0.106813714
Synthesis of dolichyl-phosphate mannose,8.014116e-08,2.0,8.014116e-08,-0.09742114,0.33373103
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),0.0,1.0,0.0,-0.09748106,0.37907103
Synthesis of glycosylphosphatidylinositol (GPI),1.0601763e-05,12.0,1.0601763e-05,-0.08955374,-0.11418322
Synthesis of pyrophosphates in the cytosol,9.2022725e-07,2.0,9.2022725e-07,-0.096792966,0.33420515
Synthesis of very long-chain fatty acyl-CoAs,1.9734225e-08,13.0,1.9734225e-08,-0.097466305,-0.1655408
Synthesis of wybutosine at G37 of tRNA(Phe),8.713785e-05,2.0,8.713785e-05,-0.032325,0.382865
"Synthesis, secretion, and deacylation of Ghrelin",5.295871e-07,6.0,5.295871e-07,-0.097085066,0.15244366
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",8.774693e-08,7.0,8.774693e-08,-0.09741545,0.106809065
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",0.00012869688,7.0,0.00012869688,-0.0012498441,0.179394
T41 mutants of beta-catenin aren't phosphorylated,4.5623387e-06,11.0,4.5623387e-06,-0.09406963,-0.072206534
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,5.073119e-07,17.0,5.073119e-07,-0.097101726,-0.3468066
"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P",0.0,1.0,0.0,-0.09748106,0.37907103
"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P",0.0,1.0,0.0,-0.09748106,0.37907103
TBC/RABGAPs,4.0767958e-05,29.0,4.0767958e-05,-0.06699741,-0.86870706
TCF7L2 mutants don't bind CTBP,2.351836e-06,3.0,2.351836e-06,-0.095722504,0.28962785
"TET1,2,3 and TDG demethylate DNA",9.804356e-06,3.0,9.804356e-06,-0.09015,0.29383394
TFAP2 (AP-2) family regulates transcription of cell cycle factors,3.3566766e-07,4.0,3.3566766e-07,-0.09723007,0.24310473
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,1.3850793e-08,6.0,1.3850793e-08,-0.0974707,0.1521526
TFAP2 (AP-2) family regulates transcription of other transcription factors,0.0,1.0,0.0,-0.09748106,0.37907103
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,4.667387e-09,3.0,4.667387e-09,-0.09747756,0.28830317
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),0.00013522152,11.0,0.00013522152,0.003628862,0.001535422
TGFBR1 KD Mutants in Cancer,1.135797e-08,5.0,1.135797e-08,-0.09747256,0.19753644
TGFBR1 LBD Mutants in Cancer,1.993401e-06,3.0,1.993401e-06,-0.09599053,0.28942555
TGFBR2 Kinase Domain Mutants in Cancer,9.922669e-08,3.0,9.922669e-08,-0.097406864,0.28835654
TGFBR2 MSI Frameshift Mutants in Cancer,4.1465387e-07,2.0,4.1465387e-07,-0.09717101,0.3339198
TICAM1 deficiency - HSE,0.0,1.0,0.0,-0.09748106,0.37907103
"TICAM1, RIP1-mediated IKK complex recruitment ",6.9613775e-06,13.0,6.9613775e-06,-0.09227579,-0.16162303
"TICAM1,TRAF6-dependent induction of TAK1 complex",1.01734195e-05,10.0,1.01734195e-05,-0.08987404,-0.023654487
TICAM1-dependent activation of IRF3/IRF7,1.8852398e-07,9.0,1.8852398e-07,-0.0973401,0.016095439
TLR3 deficiency - HSE,0.0,1.0,0.0,-0.09748106,0.37907103
TLR3-mediated TICAM1-dependent programmed cell death,4.0952787e-07,5.0,4.0952787e-07,-0.09717484,0.19776115
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,7.3987816e-05,8.0,7.3987816e-05,-0.042157747,0.10313184
TNFR1-induced NFkappaB signaling pathway,1.3243239e-06,12.0,1.3243239e-06,-0.096490815,-0.119419254
TNFR1-induced proapoptotic signaling,1.608509e-08,4.0,1.608509e-08,-0.09746904,0.24292433
TNFR1-mediated ceramide production,9.1456526e-10,2.0,9.1456526e-10,-0.09748037,0.3336863
TNFs bind their physiological receptors,2.9441502e-08,5.0,2.9441502e-08,-0.09745905,0.19754665
TP53 Regulates Metabolic Genes,0.0005190109,49.0,0.0005190109,0.29060176,-1.5064993
TP53 Regulates Transcription of Cell Cycle Genes,3.6287182e-07,24.0,3.6287182e-07,-0.09720973,-0.6645848
TP53 Regulates Transcription of Cell Death Genes,2.251552e-05,31.0,2.251552e-05,-0.080645405,-0.969779
TP53 Regulates Transcription of DNA Repair Genes,4.655083e-05,45.0,4.655083e-05,-0.06267335,-1.5916072
TRAF3 deficiency - HSE,1.0572073e-06,2.0,1.0572073e-06,-0.09669054,0.33428246
TRAF3-dependent IRF activation pathway,0.00038955058,12.0,0.00038955058,0.1937997,0.09968945
TRAF6 mediated IRF7 activation,0.00015111959,13.0,0.00015111959,0.0155164115,-0.08026245
TRAF6 mediated NF-kB activation,0.0003848124,14.0,0.0003848124,0.1902568,0.006244787
TRAIL  signaling,6.566725e-05,7.0,6.566725e-05,-0.048379328,0.14382109
TRP channels,8.1151484e-08,4.0,8.1151484e-08,-0.09742038,0.24296106
TWIK related potassium channel (TREK),0.0,1.0,0.0,-0.09748106,0.37907103
TWIK-related alkaline pH activated K+ channel (TALK),0.0,1.0,0.0,-0.09748106,0.37907103
TWIK-related spinal cord K+ channel (TRESK),0.0,1.0,0.0,-0.09748106,0.37907103
TWIK-releated acid-sensitive K+ channel (TASK),0.0,1.0,0.0,-0.09748106,0.37907103
TYSND1 cleaves peroxisomal proteins,5.4051186e-09,6.0,5.4051186e-09,-0.09747702,0.15214783
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),2.37736e-08,3.0,2.37736e-08,-0.09746328,0.28831396
Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,1.0,0.0,-0.09748106,0.37907103
Telomere C-strand (Lagging Strand) Synthesis,3.547209e-08,17.0,3.547209e-08,-0.09745453,-0.3470729
Telomere Extension By Telomerase,5.400766e-07,2.0,5.400766e-07,-0.09707722,0.33399057
Terminal pathway of complement,0.0,1.0,0.0,-0.09748106,0.37907103
Termination of O-glycan biosynthesis,6.691783e-07,6.0,6.691783e-07,-0.09698068,0.15252246
Termination of translesion DNA synthesis,2.8478707e-06,20.0,2.8478707e-06,-0.09535161,-0.48164135
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.0005832257,7.0,0.0005832257,0.33861744,0.4359228
The AIM2 inflammasome,5.286108e-06,2.0,5.286108e-06,-0.09352844,0.33666918
The IPAF inflammasome,1.0591545e-05,3.0,1.0591545e-05,-0.08956139,0.2942782
The NLRP1 inflammasome,1.5073956e-06,3.0,1.5073956e-06,-0.09635393,0.28915128
The NLRP3 inflammasome,0.00020689082,9.0,0.00020689082,0.05721854,0.13275492
The activation of arylsulfatases,1.3257637e-05,6.0,1.3257637e-05,-0.08756785,0.15962717
The fatty acid cycling model,0.0,1.0,0.0,-0.09748106,0.37907103
The proton buffering model,0.0,1.0,0.0,-0.09748106,0.37907103
The role of GTSE1 in G2/M progression after G2 checkpoint,2.3946882e-07,35.0,2.3946882e-07,-0.097302005,-1.1638921
The role of Nef in HIV-1 replication and disease pathogenesis,4.4674863e-07,22.0,4.4674863e-07,-0.09714701,-0.573767
Threonine catabolism,6.287191e-07,3.0,6.287191e-07,-0.09701095,0.28865537
Thrombin signalling through proteinase activated receptors (PARs),0.00013827626,19.0,0.00013827626,0.005912998,-0.35982248
Thromboxane signalling through TP receptor,7.489094e-06,14.0,7.489094e-06,-0.09188119,-0.20671044
Tie2 Signaling,2.568344e-07,12.0,2.568344e-07,-0.09728901,-0.12002173
Tight junction interactions,4.790427e-06,10.0,4.790427e-06,-0.093899086,-0.026692558
Tolerance by Mtb to nitric oxide produced by macrophages,0.0,1.0,0.0,-0.09748106,0.37907103
Tolerance of reactive oxygen produced by macrophages,0.0,1.0,0.0,-0.09748106,0.37907103
Toxicity of botulinum toxin type A (BoNT/A),4.5837368e-07,2.0,4.5837368e-07,-0.097138315,0.33394447
Toxicity of botulinum toxin type B (BoNT/B),9.664734e-07,2.0,9.664734e-07,-0.09675839,0.33423126
Toxicity of botulinum toxin type C (BoNT/C),3.793603e-07,3.0,3.793603e-07,-0.097197406,0.2885146
Toxicity of botulinum toxin type D (BoNT/D),2.8873768e-07,4.0,2.8873768e-07,-0.09726516,0.24307822
Toxicity of botulinum toxin type E (BoNT/E),2.9576734e-06,2.0,2.9576734e-06,-0.0952695,0.33535504
Toxicity of botulinum toxin type F (BoNT/F),3.5178355e-06,4.0,3.5178355e-06,-0.094850644,0.24490069
Toxicity of botulinum toxin type G (BoNT/G),3.213963e-06,3.0,3.213963e-06,-0.095077865,0.29011443
Toxicity of tetanus toxin (TeNT),5.643122e-08,2.0,5.643122e-08,-0.097438864,0.33371764
Trafficking and processing of endosomal TLR,3.2295775e-05,7.0,3.2295775e-05,-0.07333236,0.12498676
Trafficking of AMPA receptors,5.791599e-06,14.0,5.791599e-06,-0.093150474,-0.2076685
Trafficking of myristoylated proteins to the cilium,4.9847074e-07,4.0,4.9847074e-07,-0.097108334,0.2431966
Transcription of E2F targets under negative control by DREAM complex,8.001395e-08,11.0,8.001395e-08,-0.09742122,-0.07473629
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,1.4547102e-08,6.0,1.4547102e-08,-0.09747018,0.15215299
Transcriptional Regulation by E2F6,4.5077286e-06,22.0,4.5077286e-06,-0.09411047,-0.571475
Transcriptional activation of mitochondrial biogenesis,1.5955324e-05,19.0,1.5955324e-05,-0.085550696,-0.42885846
Transcriptional regulation by small RNAs,0.0010490275,40.0,0.0010490275,0.686914,-0.7988991
Transcriptional regulation of white adipocyte differentiation,4.6701112e-07,40.0,4.6701112e-07,-0.097131856,-1.3906898
Transfer of LPS from LBP carrier to CD14,0.0,1.0,0.0,-0.09748106,0.37907103
Transferrin endocytosis and recycling,9.46076e-05,16.0,9.46076e-05,-0.026739601,-0.24831265
Translesion Synthesis by POLH,7.0163253e-07,12.0,7.0163253e-07,-0.096956424,-0.119770706
Translesion synthesis by POLI,6.37896e-07,11.0,6.37896e-07,-0.09700408,-0.07442143
Translesion synthesis by POLK,0.00019506156,11.0,0.00019506156,0.04837338,0.035308186
Translesion synthesis by REV1,1.7687888e-05,11.0,1.7687888e-05,-0.084255196,-0.06479868
Translocation of SLC2A4 (GLUT4) to the plasma membrane,9.747769e-06,34.0,9.747769e-06,-0.09019231,-1.1131407
Translocation of ZAP-70 to Immunological synapse,2.4359142e-06,3.0,2.4359142e-06,-0.095659636,0.28967533
Transport and synthesis of PAPS,1.8866032e-06,4.0,1.8866032e-06,-0.09607039,0.24398002
Transport of Mature mRNA Derived from an Intronless Transcript,1.6864231e-09,11.0,1.6864231e-09,-0.0974798,-0.074780494
Transport of Mature mRNA derived from an Intron-Containing Transcript,1.3552911e-05,59.0,1.3552911e-05,-0.08734707,-2.245624
Transport of Ribonucleoproteins into the Host Nucleus,6.698673e-06,3.0,6.698673e-06,-0.092472225,0.29208115
Transport of fatty acids,1.298614e-08,3.0,1.298614e-08,-0.09747136,0.28830785
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,0.0,1.0,0.0,-0.09748106,0.37907103
Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,1.0,0.0,-0.09748106,0.37907103
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,9.4616276e-08,2.0,9.4616276e-08,-0.097410314,0.3337392
Transport of nucleotide sugars,1.5776181e-06,8.0,1.5776181e-06,-0.09630142,0.06226467
Transport of organic anions,1.288409e-07,4.0,1.288409e-07,-0.09738472,0.24298798
Transport of the SLBP Dependant Mature mRNA,3.505243e-05,6.0,3.505243e-05,-0.071271114,0.17192781
Transport of the SLBP independent Mature mRNA,4.1271333e-06,6.0,4.1271333e-06,-0.09439506,0.15447406
Triglyceride biosynthesis,0.00014208238,7.0,0.00014208238,0.008758973,0.18694857
Triglyceride catabolism,0.00012336344,10.0,0.00012336344,-0.005237844,0.040228155
"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",1.4501736e-06,11.0,1.4501736e-06,-0.096396714,-0.073962994
Truncations of AMER1 destabilize the destruction complex,4.2372135e-06,10.0,4.2372135e-06,-0.09431274,-0.027004788
Tryptophan catabolism,1.930904e-10,6.0,1.930904e-10,-0.097480915,0.15214488
Type I hemidesmosome assembly,1.31311335e-08,4.0,1.31311335e-08,-0.097471245,0.24292266
Type II Na+/Pi cotransporters,1.5760187e-12,2.0,1.5760187e-12,-0.09748106,0.3336858
UCH proteinases,3.4171662e-06,61.0,3.4171662e-06,-0.09492592,-2.3421152
UNC93B1 deficiency - HSE,0.0,1.0,0.0,-0.09748106,0.37907103
Ub-specific processing proteases,0.001104475,114.0,9.688377e-06,-0.090236716,-4.126114
Ubiquinol biosynthesis,3.768112e-05,5.0,3.768112e-05,-0.06930555,0.21879664
Ubiquitin-dependent degradation of Cyclin D1,2.0152402e-07,33.0,2.0152402e-07,-0.09733037,-1.073143
"Unblocking of NMDA receptor, glutamate binding and activation",2.7490078e-06,6.0,2.7490078e-06,-0.09542553,0.15369627
Unwinding of DNA,0.0007718883,9.0,0.0007718883,0.47968715,0.45163047
Uptake and function of anthrax toxins,0.00093072146,7.0,0.00093072146,0.5984523,0.6320439
Uptake and function of diphtheria toxin,4.5635436e-05,3.0,4.5635436e-05,-0.06335783,0.31405643
Urea cycle,3.6870645e-07,2.0,3.6870645e-07,-0.09720537,0.33389387
Utilization of Ketone Bodies,2.7897636e-07,3.0,2.7897636e-07,-0.09727246,0.28845796
VEGF binds to VEGFR leading to receptor dimerization,1.4639265e-07,3.0,1.4639265e-07,-0.09737159,0.28838313
VEGFR2 mediated cell proliferation,1.6644042e-05,12.0,1.6644042e-05,-0.08503572,-0.11077305
VEGFR2 mediated vascular permeability,6.87771e-05,19.0,6.87771e-05,-0.046053983,-0.3990467
VLDL assembly,0.0,1.0,0.0,-0.09748106,0.37907103
VLDL clearance,1.7391683e-05,2.0,1.7391683e-05,-0.08447668,0.34350136
VLDLR internalisation and degradation,0.00020562921,7.0,0.00020562921,0.056275193,0.2228134
Variant SLC6A14 may confer susceptibility towards obesity,0.0,1.0,0.0,-0.09748106,0.37907103
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.09748106,0.37907103
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.09748106,0.37907103
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.09748106,0.37907103
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.09748106,0.37907103
Vasopressin regulates renal water homeostasis via Aquaporins,2.9690775e-06,20.0,2.9690775e-06,-0.09526098,-0.48157296
Vif-mediated degradation of APOBEC3G,1.3151818e-07,33.0,1.3151818e-07,-0.09738272,-1.0731826
Virus Assembly and Release,0.0,1.0,0.0,-0.09748106,0.37907103
Vitamin B1 (thiamin) metabolism,2.2413961e-07,4.0,2.2413961e-07,-0.097313456,0.24304177
Vitamin B2 (riboflavin) metabolism,2.8063814e-06,4.0,2.8063814e-06,-0.09538263,0.24449913
Vitamin C (ascorbate) metabolism,1.1037374e-06,4.0,1.1037374e-06,-0.096655756,0.2435382
Vitamin D (calciferol) metabolism,5.0607356e-05,7.0,5.0607356e-05,-0.059640147,0.13532153
Vitamin E,0.0,1.0,0.0,-0.09748106,0.37907103
Vitamins,9.042277e-11,2.0,9.042277e-11,-0.097481,0.33368585
Vitamins B6 activation to pyridoxal phosphate,6.164409e-08,2.0,6.164409e-08,-0.09743497,0.33372056
Voltage gated Potassium channels,1.1106553e-06,11.0,1.1106553e-06,-0.09665058,-0.07415461
Vpu mediated degradation of CD4,4.4111673e-07,32.0,4.4111673e-07,-0.09715123,-1.0276226
VxPx cargo-targeting to cilium,4.8404405e-07,16.0,4.8404405e-07,-0.09711912,-0.3014345
WNT ligand biogenesis and trafficking,1.07483125e-07,7.0,1.07483125e-07,-0.097400695,0.1068202
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974,0.0,1.0,0.0,-0.09748106,0.37907103
WNT mediated activation of DVL,1.099963e-06,6.0,1.099963e-06,-0.09665858,0.15276557
"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",1.0385319e-06,3.0,1.0385319e-06,-0.09670451,0.28888664
WNT5A-dependent internalization of FZD4,7.0911524e-06,9.0,7.0911524e-06,-0.092178755,0.019991176
Wax biosynthesis,1.8449184e-06,3.0,1.8449184e-06,-0.096101545,0.28934178
"XAV939 inhibits tankyrase, stabilizing AXIN",7.225525e-12,2.0,7.225525e-12,-0.09748106,0.3336858
XBP1(S) activates chaperone genes,3.9167635e-06,31.0,3.9167635e-06,-0.09455235,-0.9802758
Xenobiotics,0.0,1.0,0.0,-0.09748106,0.37907103
YAP1- and WWTR1 (TAZ)-stimulated gene expression,7.0361693e-06,4.0,7.0361693e-06,-0.09221987,0.24688636
Zinc transporters,1.900757e-06,8.0,1.900757e-06,-0.0960598,0.06244705
alpha-linolenic acid (ALA) metabolism,0.00016115418,8.0,0.00016115418,0.023019632,0.15232715
c-src mediated regulation of Cx43 function and closure of gap junctions,2.0997313e-05,3.0,2.0997313e-05,-0.08178062,0.30015108
cGMP effects,5.1667914e-08,3.0,5.1667914e-08,-0.09744242,0.28832966
eNOS activation,5.249379e-06,7.0,5.249379e-06,-0.093555905,0.10972221
mRNA 3'-end processing,2.4968265e-06,46.0,2.4968265e-06,-0.09561409,-1.6618558
mRNA Capping,0.0004954398,23.0,0.0004954398,0.27297682,-0.33978605
mRNA Splicing - Major Pathway,2.8333487e-05,133.0,2.1303373e-07,-0.09732176,-5.595791
mRNA Splicing - Minor Pathway,0.00028495208,38.0,0.00028495208,0.11558771,-1.1393607
mRNA decay by 3' to 5' exoribonuclease,1.3129704e-07,14.0,1.3129704e-07,-0.09738288,-0.21086308
mRNA decay by 5' to 3' exoribonuclease,5.2901087e-05,12.0,5.2901087e-05,-0.05792504,-0.090310164
mTORC1-mediated signalling,3.1213418e-05,12.0,3.1213418e-05,-0.07414168,-0.102550335
mitochondrial fatty acid beta-oxidation of saturated fatty acids,4.12417e-05,7.0,4.12417e-05,-0.06664318,0.1300357
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,3.6117638e-06,2.0,3.6117638e-06,-0.09478041,0.3357242
p130Cas linkage to MAPK signaling for integrins,5.3504253e-05,8.0,5.3504253e-05,-0.057474036,0.09157124
p53-Dependent G1 DNA Damage Response,6.984136e-08,39.0,6.984136e-08,-0.09742884,-1.3455288
p53-Independent DNA Damage Response,2.8378924e-10,32.0,2.8378924e-10,-0.09748084,-1.0278714
p75NTR negatively regulates cell cycle via SC1,3.5479417e-08,5.0,3.5479417e-08,-0.09745453,0.19755004
p75NTR recruits signalling complexes,1.08282405e-08,10.0,1.08282405e-08,-0.097472966,-0.029390093
rRNA modification in the mitochondrion,5.2163978e-05,4.0,5.2163978e-05,-0.058476206,0.27235577
rRNA modification in the nucleus and cytosol,0.002175162,38.0,0.002175162,1.5289646,-0.0725563
snRNP Assembly,3.2052893e-07,12.0,3.2052893e-07,-0.09724139,-0.11998579
tRNA modification in the mitochondrion,4.7920917e-06,6.0,4.7920917e-06,-0.09389784,0.15484937
tRNA processing in the mitochondrion,4.1442167e-06,2.0,4.1442167e-06,-0.094382286,0.3360247
tRNA processing in the nucleus,1.3758832e-08,39.0,1.3758832e-08,-0.097470775,-1.3455606
via Dependence Receptors in the absence of ligand,1.9618244e-06,9.0,1.9618244e-06,-0.09601413,0.017096268
